Medical Care |

Medical Care

##SEVER##

/n/neurologie.uk-wuerzburg.de1.html

Les antibiotiques sont produits sous des formes pharmaceutiques telles que des pilules acheter du amoxil.

elles permettent d'injecter la quantité de préparation strictement nécessaire.

Veröffentlichungen der neurologischen universitätsklinik würzburg seit 1990

Veröffentlichungen der Neurologischen Universitätsklinik Würzburg seit 1990

( * bezeichnet Arbeiten, die unter Beteiligung von hier tätigen Wissenschaftlern überwiegend an anderen Institutionen
durchgeführt wurden)
1.
* Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 1995;11:274-80. * Adlkofer K, Frei R, Neuberg DH, Zielasek J, Toyka KV, Suter U. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci 1997;17:4662-71. Airaksinen MS, Koltzenburg M, Lewin GR, Masu Y, Helbig C, Wolf E, Brem G, Toyka KV, Thoenen H, Meyer M. Specific subtypes of cutaneous mechanoreceptors require neurotrophin-3 following peripheral target innervation. Neuron 1996;16:287-95. * Andreev NY, Dimitrieva N, Koltzenburg M, McMahon SB. Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995;63:109-115. * Anzini P, Neuberg DH, Schachner M, Nelles E, Willecke K, Zielasek J, Toyka KV, Suter U, Martini R. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 1997;17:4545-51. Apfel R, Lottspeich F, Hoppe J, Behl C, Durr G, Bogdahn U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. Melanoma Res 1992;2:327-36. Archelos JJ, Mäurer M, Jung S, Toyka KV, Hartung HP. Suppression of experimental allergic neuritis by an antibody to the intracellular adhesion molecule ICAM-1. Brain 1993;116:1043-58. Archelos JJ, Jung S, Mäurer M, Schmied M, Lassmann H, Tamatani T, Miyasaka M, Toyka KV, Hartung HP. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993;34:145-54. Archelos JJ, Roggenbuck K, Schneider-Schaulies J, Toyka KV, Hartung HP. Detection and quantification of antibodies to the extracellular domain of P0 during experimental allergic neuritis. J Neurol Sci 1993;117:197-205. Archelos JJ, Roggenbuck K, Schneider-Schaulies J, Linington C, Toyka KV, Hartung HP. Production and characterization of monoclonal antibodies to the extracellular domain of P0. J Neurosci Res 1993;35:46-53. Archelos JJ, Mäurer M, Jung S, Miyasaka M, Tamatani T, Toyka KV, Hartung HP. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. Lab Invest 1994;70:667-75. Archelos JJ, Toyka KV, Hartung HP. B cell responses to the PNS protein P0 in experimental autoimmune neuritis. J Neurol Sci 1995;128:111. Archelos JJ, Fortwangler T, Hartung HP. Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with an antibody to L-selectin. Neurosci Lett 1997;235:9-12. Archelos JJ, Hartung HP. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol Med Today 1997;3:310-21. Archelos JJ, Trotter J, Previtali S, Weissbrich B, Toyka KV, Hartung HP. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol 1998;43:15-24. * Asmus, F, Zimprich A, Naumann M, Berg D, Bertram M, Ceballos-Baumann A, Pruszak-Seel R, Kabus C, Dichgans M, Fuchs S, Muller-Myhsok B, Gasser T. Inherited myclonus-dystonia syndrome: Narrowing the 7q21-q31 Locus in German Families. Ann Neurol 2001;9:218-220. Babin-Ebell J, Misoph M, Müllges W, Elert O. Cytokine release during cardiopulmonary bypass related to roller / centrifugal pumps: effect of pump-type on cytokine release. Cardiovascular Engineering 1998;3:89-91. * Babin-Ebell J, Misoph M, Müllges W, Neukam K, Elert O. Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary baypass. Heart Vessels 1999;13:147-151. * Babin-Ebell J, Misoph M, Müllges W, Neukam K, Reese J, Elert O. Intraoperative embolus formation during cardiopulmonary bypass affects the release of S 100 B. Thorac Cardiovasc Surg 1999;47:166-169. Bauer A, Becker G, Krone A, Fröhlich T, Bogdahn U. Transcranial duplex sonography using ultrasound contrast enhancers. Clin Radiol 1996;51 Suppl 1:19-23. Bayas A, Rieckmann P, Müllges W. Tuberkulose und andere seltenere bakterielle Infektionen des.Nervensystems. In: Schwab S, Krieger D, Müllges W, Hamann GF, Hacke W (Hrsg). NeuroIntensiv, Springer 1999. Bayas A, Rieckmann P. Multiple Sklerose und Sport. Akt Neurol 2000;27:258-261. Bayas A, Hummel V, Kallmann BA, Karch C, Toyka KV, Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine 2002;19(2):55-8. Bayas A, Kruse N, Moriabadi NF, Weber F, Hummel V, Wohleben G, Gold R, Toyka KV, Rieckmann P. Modulation of cytokine mRNA expression by brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in human immune cells. Neurosci Lett 2003;335(3):155-8. Beck M, Gieß R, Magnus T, Puls I, Reiners K, Toyka KV, Naumann M. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002;73(1):68-70. Becker GM, Winkler J, Hoffmann E, Bogdahn U. Imaging of cerebral arterio-venous malformations by transcranial colour-coded real-time sonography. Neuroradiology 1990;32:280-8. Becker G, Greiner K, Kaune B, Winkler J, Brawanski A, Warmuth-Metz M, Bogdahn U. Diagnosis and monitoring of subarachnoid hemorrhage by transcranial color-coded real-time sonography. Neurosurgery 1991;28:814-20. Becker G, Winkler J, Bogdahn U. Die transkranielle farbkodierte Real-Time-Sonographie des Erwachsenen. Teil 1: Normalbefund und zerebrovaskuläre Ischämien. Ultraschall in Med 1991;12:74-79. Becker G, Winkler J, Bogdahn U. Die transkranielle farbkodierte Real-Time-Sonographie des Erwachsenen. Teil 2: Zerebrale Blutungen und Tumoren. Ultraschall Med 1991;12:211-7. Becker G, Winkler J, Bogdahn U. Die transkranielle farbkodierte Real-Time-Sonographie des Erwachsenen: Eine neue diagnostische Methode. In: Firnhaber W (Hrsg). Verhandlungen der Deutschen Gesellschaft für Neurologie, Band 6, Springer Verlag, Berlin 1991;561-562. Becker G, Perez J, Krone A, Demuth K, Lindner A, Hofmann E, Winkler J, Bogdahn U. Transcranial color-coded real-time sonography in the evaluation of intracranial neoplasms and arteriovenous malformations. Neurosurgery 1992;31:420-8. Becker G, Hofmann E, Winkler J, Bogdahn U. Differentiation between ischemic and hemorrhagic stroke by transcranial color-coded real-time sonography. J Neuroimag 1993;3: 42-47. Becker G, Bogdahn U. Transcranial color-coded real-time sonography in adults. In: Babikian VL, Wechsler LR (Hrsg). Transcranial Doppler Ultrasonography. Mosby Year Book 1993;51-69. Becker G, Lindner A, Bogdahn U. Imaging of the vertebrobasilar system by transcranial color-coded real-time sonography. J Ultrasound Med 1993;12:395-401. Becker G, Krone A, Koulis D, Lindner A, Hofmann E, Roggendorf W, Bogdahn U. Reliability of transcranial colour-coded real-time sonography in assessment of brain tumours: correlation of ultrasound, computed tomography and biopsy findings. Neuroradiology 1994;36:585-90. Becker G, Struck U, Bogdahn U, Becker T. Echogenicity of the brainstem raphe in patients with major depression. Psychiatry Res 1994;55:75-84. Becker G, Lindner A, Hofmann E, Bogdahn U. Contribution of transcranial color-coded real-time sonography to the etiopathogenetic classification of middle cerebral artery stenosis. J Clin Ultrasound 1994;22:471-7. Becker G, Bogdahn U, Strassburg HM, Lindner A, Hassel W, Meixensberger J, Hofmann E. Identification of ventricular enlargement and estimation of intracranial pressure by transcranial color-coded real-time sonography. J Neuroimaging 1994;4:17-22. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-4. Becker G, Becker T, Struck M, Lindner A, Burzer K, Retz W, Bogdahn U, Beckmann H. Reduced echogenicity of brainstem raphe specific to unipolar depression: a transcranial color-coded real-time sonography study. Biol Psychiatry 1995;38:180-4. Becker G, Bogdahn U, Gehlberg C, Frohlich T, Hofmann E, Schlief MD. Transcranial color-coded real-time sonography of intracranial veins. Normal values of blood flow velocities and findings in superior sagittal sinus thrombosis. J Neuroimaging 1995;5:87-94. Becker G, Krone A, Schmitt K, Woydt M, Hofmann E, Lindner A, Bogdahn U, Gahn G, Roosen K. Preoperative and postoperative follow-up in high-grade gliomas: comparison of transcranial color-coded real-time sonography and computed tomography findings. Ultrasound Med Biol 1995;21:1123-35. Becker G, Bogdahn U. Transcranial color Doppler imaging. In: Tegeler, Babikian LR (Hrsg). Transcranial Doppler sonography. Mosby Year Book 1995;215-243. Becker G, Naumann M, Scheubeck M, Hofmann E, Deimling M, Lindner A, Gahn G, Reiners C, Toyka KV, Reiners K. Comparison of transcranial sonography, magnetic resonance imaging, and single photon emission computed tomography findings in idiopathic spasmodic torticollis. Mov Disord 1997;12:79-88. Becker G. Bildartefakte. In: Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;112-120. Becker G, Griewing B. Untersuchungstechniken. In: Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;219-231. Becker G, Mäurer M, Bogdahn U. Intrakranielle Venen. Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;265-275. Becker G, Woydt M, Mäurer M, Krone A. Intrakranielle Tumoren. In: Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;332-341. Becker G, Becker T, Berg D, Hofmann E, Lange K, Struck M. Befunde bei neuropsychiatrischen Erkrankungen. Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;395-368. Becker G, Berg D. Befunde bei extrapyramidalen Bewegungsstörungen. Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;369-373. Becker G, Berg D, Rausch WD, Lange KW, Riederer P, Reiners K. Increased tissue copper and mangenese content of the lentiform nucleus in primary adult-onset dystonia. Ann Neurol 1999;46:260-3. Becker G, Hofmann E, Woydt M, Hulsmann U, Mäurer M, Lindner A, Becker T, Krone A. Postoperative neuroimaging of high-grade gliomas: comparison of transcranial sonography, magnetic resonance imaging, and computed tomography. Neurosurgery 1999;44:469-77. Becker G, Müllges W. Spezielle Neurologische Diagnostik in der Intensivmedizin: Ultraschall. In: Burchardi H, Larsen R, Schuster HP, Suter PM (Hrsg). Intensivmedizin, Springer 1999. Becker G, Müllges W, Engelhard K, Ringelstein EB. Extra- und Transkranielle Sonographie. In: Schwab S, Krieger D, Müllges W, Hamann GF, Hacke W (Hrsg). Neurologische Intensivmedizin, Springer 1999. Becker G, Müllges W. Spezielle Neurologische Diagnostik in der Intensivmedizin: Ultraschall. In: Burchardi H, Larsen R, Schuster HP, Suter PM (Hrsg). Intensivmedizin. Springer 1999; im Druck. Becker G, Berg D, Rausch WD, Lange KW, Riederer P, Reiners K. Increased tissue copper and mangenese content of the lentiform nucleus in primary adult-onset dystonia. Ann Neurol 1999; im Druck. Becker G, Naumann M. COMT-Hemmer. In: Riederer, Laux, Pöldinger (Hrsg). Neuro-Psychopharmakologie. 2. Auflage, Springer Verlag Wien, New York 1999;142-165. Becker G, Berg D. Neuroimaging in basal ganglia disorders: Perspectives for transcranial ultrasound. Mov Disord 2001;16:23-32. Becker G, Berg D, Lesch KP, Becker T. Basal Limbic System Alteration in Major Depression: A Hypothesis supported by Transcranial Sonography and MRI Findings. Int J Neuropsychopharmacol 2001;4:21-31. Becker G, Berg D, Francis M, Naumann M. Evidence for disturbances of copper metabolism in dystonia: From the imaging towards a new concept. Neurology 2001;57:2290-2294. Becker G, Berg D, Kruse N, Schröder U, Warmuth-Metz M, Rieckmann P, Naumann M, Reiners K. Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse. Mov Disord 2002;17(4):710-716. Becker T, Retz W, Hofmann E, Becker G, Teichmann E, Gsell W. Some methodological issues in neuroradiological research in psychiatry. J Neural Transm Gen Sect 1995;99:7-54. * Becker T, Becker G, Hofmann E, Struck M, Retz W, Beckmann H. Hirnstamm-Raphe Echogenität bei psychiatrischen Erkrankungen: Die transkranielle farbkodierte Duplexsonographie in der psychiatrischen Forschung. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg). Aktuelle Perspektiven der biologischen Psychiatrie, Springer, Wien New York 1996;685-687. Becker T, Becker G. Alteration of the basal limbic system in primary and secondary depression. In: Klingelhöffer et al. (Hrsg). New Trends in cerebral hemodynamics, Elsevier Science 1997;1-5. Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, Lindner A, Reichmann H, Riederer P, Beckmann H, Reiners K. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry 1997;63:590-6. Beer M, Sandstede J, Weilbach F, Spindler M, Buchner S, Krug A, Kostler H, Pabst T, Kenn W, Landschutz W, von Kienlin M, Toyka KV, Ertl G, Gold R, Hahn D. Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2001;173(5):399-404. Beer M, Schneider C, Kostler H, Buchner S, Sandstede J, Toyka KV, Hahn D. Quantitative analysis of energy metabolism in human muscle using SLOOP 31P-MR-spectroscopy. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002;174(5):573-8. * Bendszus M, Reents W, Franke D, Müllges W, Babin-Ebell J, Koltzenburg M, Warmuth-Metz M, Solymosi L. Brain damage after coronary artery bypass grafting. Arch Neurol 2002;59:1090-5. Bendszus M, Reiners K, Perez J, Solymosi L, Koltzenburg M. Peroneal nerve palsy caused by thrombosis of crural veins. Neurology 2002;58(11):1675-7. Benecke R, Dressler D, Moore AP, Naumann M. Cervical and axial dystonia. In: Moore AP, Naumann M (Hrsg). Handbook of botulinum toxin. Blackwell Science, Oxford 2003:158-194. Bennett DLH, Koltzenburg M, Priestley JV, Shelton DL, McMahon SB. Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci 1998;10:1282-1291. Berg D, Müllges W, Koltzenburg M, Bendszus M, Reiners K. Man-in-the-barrel syndrome caused by cervical spinal cord infarction. Acta Neurol Scand 1998;97:417-9. Berg D, Naumann M. Behandlungsstrategien beim Schreibkrampf. Neurol Rehab 1998;4:199-205. Berg D, Becker G, Reiners K. Reduction of dyskinesia and induction of akinesia induced by morphine in two Parkinsonian patients with severe sciatica. J Neural Transm 1999;106:725-8. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-31. Berg D, Grote C, Rausch WD, Mäurer M, Wesemann W, Riederer P, Becker G. Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound in Medicine Biology 1999. Berg D, Reiners K, Elferich C, Naumann M. Botulinum toxin and occupational therapy in the treatment of writer´s cramp. Neurorehabilition 1999;12:169-176. Berg D, Supprian T, Hofmann E, Zeiler B, Jäger A, Lange KW, Reiners K, Becker T, Becker G. Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 1999;246:1186-93. Berg D, Hofmann E, Preibisch M, Solymosi L, Naumann M. Cerebral activation pattern in writing tremor: a fMRI study. J Neurol Neurosurg Psychiatry 2000;69:780-786. Berg D, Mäurer M, Warmuth-Metz M, Rieckmann P, Becker G. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol 2000;57:1289-92. Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, Zeiler B, Magnus T, Rieckmann P, Becker G. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000;6:156-62. Berg D, Weishaupt A, Francis MJ, Miura N, Yang X-L, Goodyer ID, Naumann M, Koltzenburg M, Reiners K, Becker G. Changes of copper-transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia. Ann Neurol 2000;47:827-30. Berg D, Becker G, Naumann M, Reiners K. Morphine in tardive and idiopathic dystonia (short communication). J Neural Transm 2001;108(8-9):1035-41. Berg D, Naumann M, Becker G. Morphine in tardive and idiopathic dystonia. J Neural Trans 2001;108:1035-1041. Berg D, Siefker C, Ruprecht-Dörfler P, Becker G. Echo pattern of substantia nigra and its relevance for motor function and motility in elderly subjects. Neurology 2001;56:13-17. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59(6):999-1005. Bergmann I, Priestley JV, McMahon SB, Brocker EB, Toyka KV, Koltzenburg M. Analysis of cutaneous sensory neurons in transgenic mice lacking the low affinity neurotrophin receptor p75. Eur J Neurosci 1997;9:18-28. Bergmann I, Reiter R, Toyka KV, Koltzenburg M. Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75. Neurosci Lett 1998;255:87-90. Bergmann I, Dauphin M, Naumann M, Flachenecker P, Müllges W, Koltzenburg M, Sommer C. Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Muscle Nerve 1998;21:1790-3. * Besser R, Ferbert A, Hinrichs H, Kaps M, Lücking CH, Müllges W, Rappelsberger P, Stöhr M. Empfehlungen der Deutschen Gesellschaft für klinische Neurophysiologie (Deutsche EEG-Gesellschaft) zur Bestimmung des Hirntods. Klin Neurophysiol 2001;32:39-41. * Betz RC, Schoser BG, Kasper D, Ricker K, Ramirez A, Stein V, et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001;28(3):218-9. Bigalke M, Naumann M. Pharmacology of botulinum toxins. In: Jost W (Hrsg). Botulinum toxin in painful diseases. Karger Verlag Basel 2003;71-81. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994;54:5695-701. * Blumhardt LD, Vermeij BJD, Amato M, Andersen O, Edan G, Fernandez O, Filippi M, Hommes OR, Rieckmann P. A quality network model for the daily care of multiple sclerosis. Multiple Sclerosis 2000;6:231-236. Bogdahn U, Becker G, Winkler J, Greiner K, Perez J, Meurers B. Transcranial color-coded real-time sonography in adults. Stroke 1990;21:1680-8. Bogdahn U, Drenkard D, Lutz M, Apfel R, Behl C. In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours. J Cancer Res Clin Oncol 1991;117 Suppl 4:S157-63. Bogdahn U, Lau W, Hassel W, Gunreben G, Mertens HG, Brawanski A. Continuous-pressure controlled, external ventricular drainage for treatment of acute hydrocephalus--evaluation of risk factors. Neurosurgery 1992;31:898-903. Bogdahn U, Becker G, Schlief R, Reddig J, Hassel W. Contrast-enhanced transcranial color-coded real-time sonography. Results of a phase-two study. Stroke 1993;24:676-84. Bogdahn U, Fröhlich T, Becker G, Krone A, Schlief R, Schurmann J, Jachimczak P, Hofmann E, Roggendorf W, Roosen K. Vascularization of primary central nervous system tumors: detection with contrast-enhanced transcranial color-coded real-time sonography. Radiology 1994;192:141-8. 100. Bogdahn U, Becker G, Schlachetzki F. Echosignalverstärker und transkranielle Farbduplex- Sonographie. Blackwell, Berlin, Wien u.a. 1998. 101. Bourde O, Kiefer R, Toyka KV, Hartung HP. Quantification of interleukin-6 mRNA in wallerian degeneration by competitive reverse transcription polymerase chain reaction. J Neuroimmunol 1996;69:135-40. 102. * Braun N, Michel U, Ernst BP, Metzner R, Bitsch A, Weber F, Rieckmann P. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996;215:75-8. 103. * Buchwald B, Weishaupt A, Toyka KV, Dudel J. Immunoglobulin G from a patient with Miller- Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995;201:163-6. 104. * Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann Neurol 1998;44:913-22. 105. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998;10:281-90. 106. Buchwald B, Dudel J, Toyka KV. Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome. Ann N Y Acad Sci 1998;841:659-69. 107. Buchwald B, Ahangari R, Toyka KV. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett 2002;334(1):25-8. 108. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002;51(6):673-80. 109. * Bütefisch CM, Sawaki L, Davis BD, Waldvogel D, Classen J, Kopylev L, Cohen LG. Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol 2002;51:59-68. 110. * Bufler J, Kahlert S, Tzartos S, Toyka KV, Maelicke A, Franke C. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor. J Physiol (Lond) 1996;492:107-14. 111. * Burger R, Tonn JC, Vince GH, Hofmann E, Reiners K, Roosen K. Median corpectomy in cervical spondylotic multisegmental stenosis. Zentralbl Neurochir 1996;57:62-9. 112. * Bushe KA, Naumann M, Warmuth-Metz M, Meixensberger J, Muller J. Maffucci's syndrome with bilateral cartilaginous tumors of the cerebellopontine angle. Neurosurgery 1990;27:625-8. 113. Buttmann M, Marziniak M, Toyka KV, Sommer C, Altland K. "Sporadic" familial amyloidotic polyneuropathy in a German patient with B cell lymphocytic leukaemia. J Neurol Neurosurg Psychiatry 2002;73(1):86-7. 114. * Carenini S, Schachner M, Martini R. Cytochalasin D disrupts the restricted localization of N- CAM, but not of L1, at sites of Schwann cell-neurite and Schwann cell-Schwann cell contact in culture. J Neurocytol 1998;27:453-458. 115. Carenini S, Montag D, Schachner M, and Martini R. MAG-deficient Schwann cells myelinate dorsal root ganglion neurons in culture. Glia 1998;22:213-220. 116. Carenini S, Montag D, Schachner M, Martini R. Subtle roles of N-CAM and MAG during Schwann cell spiralling in P0-deficient mice. Glia 1999;27:203-212. 117. Carenini S, Neuberg D, Schachner M, Suter U, Martini R. Localization and functional roles of PMP22 in peripheral nerves of P0-deficient mice. Glia 1999:28: 256-264. 118. Carenini S, Martini R. Myelin-defiziente Mutanten des peripheren Nervensystems: Chancen für Behandlungsstrategien erblicher Neuropathien? Neuroforum 2000;VI/3:216-28. 119. Carenini S, Mäurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Paivich G, Martini R. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 2001;152(2):301-8. 120. Carroll P, Lewin GR, Koltzenburg M, Toyka KV, Thoenen H. A role of BDNF in mechanosensation. Nat Neurosci 1998;1:42-46. 121. Chan A, Gold R, Arp S, Pflughaupt KW, Toyka KV, Reichmann H. Standardisierter Fahrradergometertest bei mitochondrialen Myopathien. Indikation, Storfaktoren und klinisch aussagekraftige Parameter. Nervenarzt 1998;69:472-84. 122. Chan A, Reiter R, Wiese S, Fertig G, Gold R. Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models. Histochem Cell Biol 1998;110:553-8. 123. Chan A, Reichmann H, Kogel A, Beck A, Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-5. 124. Chan A, Magnus T, Gold R. Phagocytosis of apoptotic inflammatory cells by microglia and modulation by different cytokines: a mechanism for removal of apoptotic cells in the inflamed nervous system. Glia 2001;33:87-95. 125. Chan A, Papadimitriou C, Graf W, Toyka KV, Gold R. Effects of polyclonal immunoglobulins (IVIg) and other immunomodulatory agents on microglial phagocytosis of apoptotic inflammatory T-cells. J Neuroimmunol 2003;135(1-2):161-165. 126. Constable AL, Armati PJ, Toyka KV, Hartung HP. Production of prostanoids by Lewis rat Schwann cells in vitro. Brain Res 1994;635:75-80. 127. Cooke JD, Hefter H, Brown SH, Toyka KV, Freund HJ. Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy. Electromyogr Clin Neurophysiol 1994;34:87-93. 128. * Dahme M, Bartsch U, Martini R, Anliker B, Schachner M, Mantei N. Disruption of the gene coding for the cell adhesion molecule L1 leads to malformations of the nervous system in mice. Nature Genet 1997;17:346-349. 129. Debus ES, Müllges W, Sailer MA, Reith HB, Franke S. Left cerebral hemineglect following carotid TEA: diagnostic, pathogenetic, and therapeutic considerations. Int Surg 1998;83:194-7. 130. Dittrich F, Ochs G, Grosse-Wilde A, Berweiler U, Yan Q, Miller JA, Toyka KV, Sendtner M. Pharmacokinetics of intrathecally applied BDNF and effects on spinal motoneurons. Exp Neurol 1996;141:225-39. 131. * Dodel R, Kirchner A, Koehne-Volland R, Ceballos-Baumann A, Naumann M, Richter H, Szucs T, Oertel W. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997;12:695-706. 132. Dorn T, Müllges W, Toyka KV. Ein Fall von Romano-Ward-Syndrom und Epilepsie. In: Jerusalem F, Ries F (Hrsg). Verhandlungen der Deutschen Gesellschaft für Neurologie 8, Springer, Berlin 1994;284-5. 133. * Dreetz-Gjerstad M, Tandrup T, Koltzenburg M, Jakobsen J. Predominant loss of B-cell in dorsal root ganglia of mice lacking the neurotrophin receptor p75. J Anat 1999;200:81-87. 134. Enders U, Karch H, Toyka KV, Michels M, Zielasek J, Pette M, Heesemann J, Hartung HP. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders. Ann Neurol 1993;34:136-44. 135. Enders U, Toyka KV, Hartung HP, Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuroimmunol 1997;76:112-6. 136. Enders U, Lobb R, Pepinsky RB, Hartung HP, Toyka KV, Gold R. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain 1998;121:1257-66. 137. Flachenecker P, Toyka KV, Hartung HP. Aktive Schutzimpfungen bei multipler Sklerose. Dtsch Med Wochenschr 1995;120:1513-6. 138. Flachenecker P, Hartung HP. Multiple Sklerose und Schwangerschaft. Übersicht und Stand der europäischen multizentrischen PRIMS-Studie. Nervenarzt 1995;66:97-104. 139. Flachenecker P, Müllges W, Wermuth P, Hartung HP, Reiners K. Eyeball pressure testing in the evaluation of serious bradyarrhythmias in Guillain-Barré syndrome. Neurology 1996;47:102-8. 140. Flachenecker P, Hartung HP. Krankheitsverlauf und Prognose der multiplen Sklerose. 1. Teil: Der natürliche Krankheitsverlauf. Nervenarzt 1996;67:435-43. 141. Flachenecker P, Hartung HP. Krankheitsverlauf und Prognose der multiplen Sklerose. 2. Teil: Prädiktiver Wert klinischer und paraklinischer Faktoren. Nervenarzt 1996;67:444-51. 142. Flachenecker P, Hartung HP. EDMUS--eine europäische Datenbank für multiple Sklerose. Eine kurze Vorstellung bereits laufender und noch geplanter multizentrischer Studien im Rahmen der "Europäischen konzertierten Aktion für multiple Sklerose". Nervenarzt 1996;67:277-82. 143. Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study. Brain 1997;120:1885-94. 144. Flachenecker P, Wermuth P, Hartung HP, Reiners K. Quantitative assessment of cardiovascular autonomic function in Guillain-Barré syndrome. Ann Neurol 1997;42:171-9. 145. Flachenecker P, Kiefer R, Naumann M, Handwerker M, Reichmann H. Distal muscular dystrophy of Miyoshi type. Report of two cases and review of the literature. J Neurol 1997;244:23-9. 146. Flachenecker P, Gold R. Multiple Sklerose. Aktuelle Vorstellungen zu Pathogenese, Klinik und Therapie. Med Welt 1998;49:438-449. 147. Flachenecker P, Mansouri Taleghani B, Gold R, Grossmann R, Wiebecke D, Toyka KV. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophospamide. Transfus Sci 1998;19(suppl):43-46. 148. Flachenecker P, Reiners K. Autonomic nervous system testing. Muscle Nerve 1998;21:680. 149. Flachenecker P, Hartung HP. Impfkomplikationen des ZNS. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg). Neurologie in Klinik und Praxis. 3rd ed. Stuttgart: Georg Thieme Verlag 1999:893-896. 150. Flachenecker P, Janka M, Goldbrunner R, Toyka KV. Clinical outcome of sural nerve biopsy: a retrospective study. J Neurol 1999;246:93-96. 151. Flachenecker P, Reiners K. Twenty-four-hour heart rate power spectrum for evaluation of autonomic dysfunction in Guillain-Barré syndrome. J Neurol Sci 1999;165:144-153. 152. Flachenecker P, Rieckmann P. Klinik und Therapie der Multiplen Sklerose. In: Zettl UK, Mix E (Hrsg). Klinische Neuroimmunologie. Berlin: Walter de Gruyter 1999;135-150. 153. Flachenecker P, Toyka KV, Gold R. Glukokortikoid-Therapie neurologischer Autoimmunerkrankungen. Münch Med Wschr 1999;141:230-234. 154. Flachenecker P, Toyka KV. Frühdiagnostik der multiplen Sklerose. Allgemeinarzt 1999;17:1466- 155. Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999;246:578-586. 156. Flachenecker P, Lem K, Müllges W, Reiners K. Detection of serious bradyarrhythmias in Guillain-Barré syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum. Clin Auton Res 2000;10:185-191. 157. Flachenecker P, Moriabadi N, Niewiesk S, Rieckmann P. Immunization and multiple sclerosis: clinical and immunological implications. Int MS J 2000;7:79-87. 158. Flachenecker P, Rieckmann P. Multiple Sklerose - Konsensus-Empfehlungen zur immunprophylaktischen Stufentherapie. Therapie aktuell 2000;2:6-10. 159. Flachenecker P, Toyka KV. Frühdiagnostik der multiplen Sklerose. Versicherungsmedizin 2000;52:119-124. 160. Flachenecker P, Toyka KV. Immuntherapie der multiplen Sklerose. Teil I: Kortikosteroidbehandlung des akuten Schubes - Interferon-β-Therapie. Allgemeinarzt 2000;13:993-995. 161. Flachenecker P, Toyka KV. Immuntherapie der multiplen Sklerose. Teil II: Alternativen zur Interferon-β-Therapie. Allgemeinarzt 2000;13:1069-1072. 162. Flachenecker P. Klinische Standarduntersuchungen autonomer Funktionen: Parasympathikus- Funktionen. In: Jörg J (Hrsg). Autonome Diagnostik und Schlafpolygraphie in Klinik und Praxis. Darmstadt: Steinkopff-Verlag 2001:3-22. 163. Flachenecker P. Störungen der Herz-Kreislauf-Funktion und des Schlafes bei der Multiplen Sklerose. In: Zettl UK, Mix E (Hrsg). Multiple Sklerose. Kausalorientierte, symptomatische und rehabilitative Therapie. Heidelberg: Springer-Verlag 2001:215-234. 164. Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001;7(5):327-34. 165. Flachenecker P, Toyka KV, Reiners K. Herzrhythmusstörungen beim Guillain-Barré-Syndrom: Eine Übersicht zur Diagnostik einer seltenen, aber potenziell lebensbedrohlichen Komplikation. Nervenarzt 2001;72(8):610-617. 166. Flachenecker P, Jung S, Rieckmann P, Toyka KV. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis – a cross-sectional pilot study. J Neurol 2002;249(8):1001-1003. 167. Flachenecker P, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8(6):523-6. 168. Flachenecker P, Rieckmann P. Early Intervention in Multiple Sclerosis: Better Outcomes for Patients and Society? Drugs 2003; im Druck. 169. * Franke C, Iaizzo PA, Hatt H, Spittelmeister W, Ricker K, Lehmann-Horn F. Altered Na+ channel activity and reduced Cl- conductance cause hyperexcitability in recessive generalized myotonia (Becker). Muscle Nerve 1991;14(8):762-70. 170. Frei R, Dowling J, Carenini S, Fuchs E, Martini R. Myelin formation by Schwann cells in the absence of ß4-integrin. Glia 1999;27:269-274. 171. Frei R, Mötzing S, Kinkelin I, Schachner M, Koltzenburg M, Martini R. Loss of distal axons and sensory Merkel cells and features indicative of muscle denervation in hindlimbs of P0-deficient mice. J Neurosci 1999;19:6058-6067. 172. * Freund HJ, Reiners K. Neurologie. In: Helmich P (Hrsg). Allgemeinmedizin. München - Wien - Baltimore: Urban & Schwarzenberg 1993;155–167. 173. Gaupp S, Hartung HP, Toyka K, Jung S. Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens. J Neuroimmunol 1997;79:129-37. 174. George A, Marziniak M, Schäfers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 2000;88:267-275. 175. * Geuder KI, Marx A, Witzemann V, Schalke B, Toyka K, Kirchner T, Müller-Hermelink HK. Pathogenetic significance of fetal-type acetylcholine receptors on thymic myoid cells in myasthenia gravis. Dev Immunol 1992;2:69-75. 176. * Geuder KI, Marx A, Witzemann V, Schalke B, Kirchner T, Müller-Hermelink HK. Genomic organization and lack of transcription of the nicotinic acetylcholine receptor subunit genes in myasthenia gravis-associated thymoma. Lab Invest 1992;66:452-8. 177. Giegerich G, Stangel M, Torres-Nagel N, Hunig T, Toyka KV. Sequence and diversity of rat T- cell receptor Tcra V8 gene segments. Immunogenetics 1995;42:304-5. 178. Gieß R, Goetz R, Schrank B, Ochs G, Sendtner M, Toyka K. Potential implications of a ciliary neurotrophic factor gene mutation in a German population of patients with motor neuron disease. Muscle Nerve 1998;21:236-8. 179. Gieß R, Rieckmann P, Müllges W. Juvenile zerebrale Ischämien durch Designerdrogen. Dtsch Med Wochenschr 1998;123:1308-12. 180. Gieß R, Müllges W. Einseitige Mydriasis nach Rückschnitt einer Engelstrompete. Deutsch Med WSchr 1999;44:1456. 181. Gieß R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Toyka KV. Injections of Botulinum Toxin A into the Salivary Glands Improves Sialorrhea in Amyotrophic Lateral Sclerosis. J Neurol Neurosurg Psychiatry 2000;69:121-123. 182. Gieß R, Holtmann B, Braga M, Grimm T, Muller-Myhsok B, Toyka KV, Sendtner M. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet 2002;70(5):1277-86. 183. Gieß R, Mäurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, Sendtner M, Rieckmann P. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 2002;59(3):407-9. 184. Gieß R, Werner E, Beck M, Magnus T, Reiners C, Toyka K, Naumann M. Impaired salivary gland function reveals autonomic dysfunction in amyotrophic lateral sclerosis. J Neurol 2002;249:1246-1249. 185. Gold R, Schuknecht B, Kappos L. Multiple Sklerose und ihre Abgrenzung von anderen Krankheitsbildern. Fallbeispiele mit differentialdiagnostischen Überlegungen. Med Klin 1990;85:454-8. 186. Gold R, Kappos L. Faziale Myokymie durch pontine Läsionen und zentrales Fieber bei multipler Sklerose--Kasuistik. Schweiz Rundsch Med Prax 1991;80:1327-9. 187. Gold R, Kress W, Meurers B, Müller CR, Reichmann H. Die Bedeutung von Dystrophinanalysen bei adulten Myopathien. Untersuchungsmethoden, Fallbeispiele und derzeitige pathogenetische Vorstellungen. Nervenarzt 1991;62:360-8. 188. Gold R, Kress W, Meurers B, Meng G, Reichmann H, Müller CR. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992;15:214-8. 189. Gold R, Wietholter H, Rihs I, Lower J, Kappos L. Frühsommer-Meningoenzephalitis-Impfung. Indikation und kritische Beurteilung neurologischer Impfkomplikationen. Dtsch Med Wochenschr 1992;117:112-6. 190. Gold R, Reichmann H. Muscle pathology correlates with permanent weakness in hypokalemic periodic paralysis: a case report. Acta Neuropathol (Berl) 1992;84:202-6. 191. Gold R, Kress W, Reichmann H, Müller CR. The use of monoclonal antibodies in diagnostic tests for Becker and Duchenne muscular dystrophy. J Neurol 1993;240:21-4. 192. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71:219-25. 193. Gold R, Kress W, Bettecken T, Reichmann H, Müller CR. A 400-kb tandem duplication within the dystrophin gene leads to severe Becker muscular dystrophy. J Neurol 1994;241:331-4. 194. Gold R, Toyka KV, Hartung HP. Synergistic effect of IFN-gamma and TNF-alpha on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol 1995;165:65-70. 195. * Gold R, Giegerich G, Hartung HP, Toyka KV. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci U S A 1995;92:5850-4. 196. * Gold R, Hartung HP, Toyka KV. Therapie mit Immunglobulinen bei neurologischen Autoimmunerkrankungen. Indikationen und Wirkungsmechanismen. Fortschr Neurol Psychiatr 1995;63:17-29. 197. * Gold R, Pepinsky RB, Zettl UK, Toyka KV, Hartung HP. Lipocortin-1 (annexin-1) suppresses activation of autoimmune T cell lines in the Lewis rat. J Neuroimmunol 1996;69:157-64. 198. * Gold R, Zielasek J, Schröder JM, Sellhaus B, Cedarbaum J, Hartung HP, Sendtner M, Toyka KV. Treatment with ciliary neurotrophic factor does not improve regeneration in experimental autoimmune neuritis of the Lewis rat. Muscle Nerve 1996;19:1177-80. 199. Gold R, Schmied M, Tontsch U, Hartung HP, Wekerle H, Toyka KV, Lassmann H. Antigen presentation by astrocytes primes rat T lymphocytes for apoptotic cell death. A model for T-cell apoptosis in vivo. Brain 1996;119:651-9. 200. Gold R, Zielasek J, Kiefer R, Toyka KV, Hartung HP. Secretion of nitrite by Schwann cells and its effect on T-cell activation in vitro. Cell Immunol 1996;168:69-77. 201. Gold R, Bogdahn U, Kappos L, Toyka KV, Baumgartner ER, Fowler B, Wendel U. Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset. J Neurol Neurosurg Psychiatry 1996;60:107-8. 202. Gold R, Seibel P, Reinelt G, Schindler R, Landwehr P, Beck A, Reichmann H. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur Neurol 1996;36:191-6. 203. Gold R, Hartung HP, Lassmann H. T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 1997;20:399-404. 204. Gold R, Rieckmann P. Klinische und pathogenetische Grundlagen der Multiplen Sklerose. Unimed Verlag 1998. 205. Gold R, Müllges W, Toyka KV. Guillain-Barré-Syndrom (akute entzündliche Polyradikuloneuritis [AIDP]) und chronisch entzündliche demyelinisierende Poyradikuloneuritis (CIDP). In: Schwab S, Krieger D, Müllges W, Hamann GF, Hacke W (Hrsg). Neurologische Intensivmedizin, Springer 1999. 206. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001;117(1-2):1-8. 207. Gold R, Stadelmann C, Brück W, Lassmann H. Apoptotischer Zelltod bei neuroinflammatorischen und neurodegenerativen Erkrankungen. Akt Neurol 2001;28:17-25. 208. Gold R, Linington C. Devic's disease: bridging the gap between laboratory and clinic. Brain 2002;125:1425-1427. 209. Gold R, Dalakas MC, Toyka KV. Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2003;2:22-32. 210. Gold R, Stangel M, Müllges W. Guillain-Barré Syndrom: Diagnose, Differentialdiagnose und Therapie. Intensivmed und Notfallmedizin 2003; im Druck. 211. Grauer O, Offenhäusser M, Schmidt J, Toyka KV, Gold R. Glukokortikosteroid-Pulstherapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktische Empfehlungen. Nervenarzt 2001(8);72:577-589. 212. Grauer O, Wohlleben G, Kämpgen E, Toyka KV, Gold R. Generation of highly enriched mature dendritic cells from rat bone marrow cultures by stimulation with rat GM-CSF and rat IL-4. Histochem Cell Biol 2002;117:351-362. 213. * Griewing B, Becker G. Gefäßanatomie und Flußgeschwindigkeiten. In: Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;238-250. 214. * Grossmann R, Geisen U, Merati G, Müllges W, Schambeck CM, Schwender S. Genetic risk factors in young adults with „cryptogenic" cerebrovascular ischemic stroke. Blood Coagul Fibrinolysis 2002;13:583-90. 215. * Guénard V, Schweitzer B, Flechsig E, Hemmi S, Martini R, Suter U, Schachner M. Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 1998;25:165-178. 216. * Guénard V, Schweitzer B, Flechsig E, Hemmi S, Martini R, Suter U, Schachner M. Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 1999;25:165-178. 217. Gunreben G, Meurers B, Bogdahn U. Einzelpotentialanalyse in der Myopathiediagnostik: Entwicklung quantitativer EMG-Parameter. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 1990;21:150-6. 218. Gunreben G, Bogdahn U. Real-time sonography of acute and chronic muscle denervation. Muscle Nerve 1991;14:654-64. 219. * Hackstein H, Bitsch A, Bohnert A, Hofmann H, Weber F, Linington C, Mäurer M, Poser S, Rieckmann P, Bein G. The interleukin-4 receptor variant R551 influences susceptibility to major clinical forms of multiple sclerosis. J Neuroimmunol 2001;113:240-248. 220. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44:780-8. 221. Hadden RDM, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RAC, Toyka KV, and the Plasma Exchange/Sandoglobulin Guillain-Barré-Syndrome Trial Group. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001;56(6):758-65. 222. Hamann GF, Müllges W. Neurologische Intensivmedizin: Aufgaben, Organisation, Basisversorgung. In: Schwab S, Krieger D, Müllges W, Hamann GF, Hacke W (Hrsg). Neurologische Intensivmedizin, Springer 1999. 223. Handwerker HO, Koltzenburg M. Vegetatives Nervensystem. In: Speckmann E-J, Deetjen P (Hrsg). Lehrbuch der Physiologie. 1. Auflage. München: Urban & Schwarzenberg, 1992;483-510. 224. Handwerker HO, Koltzenburg M. Vegetatives Nervensystem. In: Speckmann E-J, Deetjen P (Hrsg). Physiologie. 2. Auflage. München: Urban & Schwarzenberg, 1994;511-538. 225. Handwerker HO, Koltzenburg M. Vegetatives Nervensystem. In: Speckmann E-J, Deetjen P (Hrsg). Physiologie. 3. Auflage. München: Urban & Fischer 1999;541-566. 226. Hartung HP, Heininger K, Toyka KV. Neue Aspekte zur Pathogenese und Therapie des Guillain-Barré-Syndroms und der chronischen Polyneuritis. Nervenarzt 1990;61:197-207. 227. Hartung HP, Schafer B, van der Meide PH, Fierz W, Heininger K, Toyka KV. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. Ann Neurol 1990;27:247-57. 228. Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990;40:215-8. 229. Hartung HP, Toyka KV. T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1990;27 Suppl:S57-63. 230. Hartung HP, Schäfer B, Reiners K, Heininger K, Toyka KV. Intrathecal complement activation in inflammatory and demyelinating diseases of PNS and CNS. In: Gonsette RE, Delmotte P (Hrsg). Recent advances in MS therapy. Amsterdam: Excerpta Medica 1990;243-247. 231. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53. 232. Hartung HP, Jung S, Stoll G, Zielasek J, Schmidt B, Archelos JJ, Toyka KV. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992;40:197-210. 233. Hartung HP, Michels M, Reiners K, Seeldrayers P, Archelos JJ, Toyka KV. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-5. 234. Hartung HP, Zielasek J, Toyka KV. Reactive nitrogen intermediates: effector molecules of immune-mediated inflammatory nervous system disorders? Ann Neurol 1993;33:422. 235. Hartung HP. Immune-mediated demyelination. Ann Neurol 1993;33:563-7. 236. Hartung HP, Gold R, Zielasek J, Archelos JJ, Toyka KV. Therapie der akuten Polyradikuloneuritis (Guillain-Barré-Syndrom). Nervenarzt 1994;65:807-18. 237. Hartung HP, Reiners K, Toyka KV, Pollard JD. Guillain-Barré syndrome and CIDP. In: Hohlfeld R (Hrsg). Immunology of Neuromuscular Disease. Dordrecht - Boston - London: Kluwer Academic Publishers 1994:33–104. 238. Hartung HP, Reiners K, Michels M, Hughes RA, Heidenreich F, Zielasek J, Enders U, Toyka KV. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies. Neurology 1994;44:1153-8. 239. Hartung HP, Hohlfeld R. Interferon-beta zur Behandlung der schubformig verlaufenden Multiplen Sklerose.Nervenarzt 1994;65:139-45. 240. Hartung HP. Experimental allergic neuritis and Guillain-Barré syndrome: immune mechanisms. A short review. Acta Neurol Belg 1994;94:120-3. 241. Hartung HP, Reiners K, Archelos JJ, Michels M, Seeldrayers P, Heidenreich F, Pflughaupt KW, Toyka KV. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-93. 242. Hartung HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, Toyka KV. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995;45:S22-32. 243. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part II. Muscle Nerve 1995;18:154-64. 244. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barre syndrome-Part I. Muscle Nerve 1995;18:137-53. 245. Hartung HP, Zielasek J, Jung S, Toyka KV. Effector mechanisms in demyelinating neuropathies. Rev Neurol (Paris) 1996;152:320-7. 246. Hartung HP, Kiefer R, Gold R, Toyka KV. Autoimmunity in the peripheral nervous system. Baillieres Clin Neurol 1996;5:1-45. 247. Hartung HP, Willison H, Jung S, Pette M, Toyka KV, Giegerich G. Autoimmune responses in peripheral nerve. Springer Semin Immunopathol 1996;18:97-123. 248. Hartung HP. Pathogenese der Multiplen Sclerosis: Stand der Forschung. Wien Med Wochenschr 1996;146:520-7. 249. Hartung HP, Pette M, Reiners K, Toyka K V. Akutes Guillain-Barré-Syndrom. 250. Nervenheilkunde 1996;15:11–17. 251. Hartung HP, Rieckmann P. Pathogenesis of immune-mediated demyelination in the CNS. J Neural Transm Suppl 1997;50:173-81. 252. Hartung HP, Hohlfeld R. Interferon-beta 1a in der Therapie der schubformigen multiplen Sklerose. Nervenarzt 1997;68:525-7. 253. Hartung HP, Flachenecker P, Weilbach FX, Rieckmann P. Die PRISMS-Studie. Interferon beta- 1a bei schubförmiger multipler Sklerose. Nervenarzt 1999;70:182-185. 254. Harvey GK, Toyka KV, Hartung HP. Effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo. J Neurol Sci 1994;125:102-9. 255. Harvey GK, Gold R, Hartung HP, Toyka KV. Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 1995;118:1263-72. 256. Harvey GK, Toyka KV, Zielasek J, Kiefer R, Simonis C, Hartung HP. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve 1995;18:388-94. 257. * Hefter H, Logigian E, Witte OW, Reiners K, Freund HJ. Oscillatory activity in different motor subsystems in palatal myoclonus. A case report. Acta Neurol Scand 1992;86:176-83. 258. * Hefter H, Witte OW, Reiners K, Niedermeyer E, Freund HJ. High frequency bursting during rapid finger movements in an unusual case of epilepsia partialis continua. Electromyogr Clin Neurophysiol 1994;34:95-103. 259. * Heidenreich F, Leifeld L, Reiners K: Antikörper gegen das Gangliosid GM1 im Serum und in Lypmphozytenkulturen bei Erkrankungen des Motoneurons. In: Pongratz D, Reimers CD, Schmidt-Ackert M (Hrsg). Aktuelle Myologie. München - Wien - Baltimore: Urban & Schwarzenberg 1992;299–302. 260. * Heininger K, Gibbels E, Besinger UA, Borberg H, Hartung HP, Grabensee B, Toyka KV. Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyneuropathy. Prog Clin Biol Res 1990;337:275-81. 261. Held M, Schneider C, Fleischer K, Jany B. Ein Patient mit Muskelschmerzen nach einer Tropenreise. Myokardbeteiligung bei der proximalen myotonen Myopathie. Dtsch Med Wochenschr 1998;123:1201-6. 262. * Hennerici M, Toyka KV. Paraneoplastische Syndrome am Nervensystem. Internist (Berl) 1990;31:499-504. 263. * Herdmann J, Reiners K, Freund HJ. Disturbances of motor unit recruitment and firing rate modulation in polyneuropathies. In: Lovelace RE, Shapiro HK (Hrsg). Charcot-Marie-Tooth-Disorders: Pathophysiology, molecular genetics and therapy, New York: Wiley-Liss 1990;141–146. 264. Heuss D, Müller-Felber W, Schulte-Mattler W, Dengler R, Toyka K, Sommer C. Diagnostik und Therapie der Multifokalen Motorischen Neuropathie (MMN). Nervenheilkunde 2002;100:68-81. 265. Heuss D, Schlotter-Weigel B, Sommer C. Klinik, Diagnostik und Therapie der vaskulitischen Neuropathie. Fortschritte Neurologie Psychiatrie 2003;71:172-86. 266. * Hofmann UB, Ogilvie P, Müllges W, Brocker EB, Hamm H. Congenital unilateral speckled lentiginous blue nevi with asymmetric spinal muscular atrophy. J Am Acad Dermatol 1998;39:326-9. 267. Hofmann E, Ochs G, Pelzl A, Warmuth-Metz M. The corticospinal tract in amyotrophic lateral sclerosis: an MRI study. Neuroradiology 1998;40:71-5. 268. Hoitsma E, Marziniak M, Faber CG, Reulen JPH, Sommer C, Baets MD, Drent M. Small fiber neuropathy in sarcoidosis. Lancet 2002;2359:085-2086. 269. * Homberg V, Reiners K, Toyka KV. Reversible conduction block in human ischemic neuropathy after ergotamine abuse. Muscle Nerve 1992;15:467-70. 270. Hummel V, Kallmann B, Füller T, Wagner S, Bayas A, Tonn JC, Benveniste E, Toyka KV, Rieckmann P. Production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules. J Neuropathol Exp Neurol 2001;60(4):320–327. 271. * Hund E, Jansen O, Koch MC, Ricker K, Fogel W, Niedermaier N, et al. Proximal myotonic myopathy with MRI white matter abnormalities of the brain. Neurology 1997;48(1):33-7. 272. * Hund M, Kinkelin I, Naumann M, Hamm H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 2002;138:539-541. 273. * Iaizzo PA, Franke C, Hatt H, Spittelmeister W, Ricker K, Rudel R, et al. Altered sodium channel behaviour causes myotonia in dominantly inherited myotonia congenita. Neuromuscul Disord 1991;1(1):47-53. 274. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944-51. 275. Jachimczak P, Schwulera U, Bogdahn U. In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells. J Neurosurg 1994;81:579-86. Fabel-Schulte K, Hessdorfer B, Brysch W, Schlingensiepen KH, Blesch A, Bogdahn U. Transforming growth factor-beta-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleotides. Cell Immunol 1995;165:125-33. 277. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996;65:332-7. 278. Jäger AH, Bogdahn U, Pfeufer B, Richter J, Apfel R, Dekant A. In vitro studies on interaction of 4-hydroperoxy-ifosfamide and radiotherapy in malignant gliomas. Anticancer Res 1993;13:2221-7. 279. Jäger AH, Bogdahn U, Apfel R, Pfeufer B, Dekant A. In vitro studies on interaction of 4- hydroperoxyifosfamide and 2- mercaptoethanesulphonate in malignant gliomas. J Cancer Res Clin Oncol 1993;119:721-6. 280. Jänig W, Koltzenburg M. Possible ways of sympathetic-afferent interactions. In: Jänig W, Schmidt RF (Hrsg). Pathophysiological Mechanisms of Reflex Sympathetic Dystrophy. Weinheim: VCH 1992;213-243. 281. Jänig W, Koltzenburg M. Pain arising from the urogenital tract. In: Maggi CA (Hrsg). Nervous Control of the Urogenital System. Chur: Harwood Publishers 1993;525-578. 282. * Jander S, Lausberg F, Stoll G. Differential recruitment of CD8+ macrophages during Wallerian degeneration in the peripheral and central nervous system. Brain Pathology 2001;11: 27-38. 283. * Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Müller W, Sandmann W, Stoll G. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001;32: 850-854. 284. * Jander S, Schroeter M, Peters O, Witte OW, Stoll G. Spreading depression induces proinflammatory cytokine gene expression in the cerebral cortex of rats. Cerebral Blood Flow Metabolism 2001;21:218-225. 285. * Jander S, Stoll G. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 2001;114:253-258. 286. * Jander S, Bussini S, Neuen-Jacob E, Menge T, Bosse F, Müller HW, Stoll G. Osteopontin: a novel axon-regulated Schwann cell gene. J Neurosci Res 2002;67:156-166.
287. * Jander S, Schroeter M, Stoll G. Interleukin-18 expression after focal ischemia: association with the late stage inflammatory response. J Cerebral Blood Flow Metabolism 2002;22:62-70. 288. * Jander S, Stoll G. Increased expression of the interferon-gamma-inducing cytokine interleukin- 18 in myasthenia gravis. Neurology 2002;59:287-289. 289. * Jansen O, Brückmann H, Müllges W, Kessler C. Abhängigkeit der Hirninfarktmuster von der Gefäßmorphologie bei Karotisdissekaten. Klin Neuroradiol 1993;3:5-7. 290. Jost W, Naumann M. Botulinum toxin in neuro-urology. Mov Disord 2003; im Druck. 291. Jung S, Schluesener HJ, Toyka K, Hartung HP. T cell vaccination does not induce resistance to experimental autoimmune neuritis. J Neuroimmunol 1991;35:1-11. 292. Jung S, Krämer S, Schluesener HJ, Hünig T, Toyka K, Hartung HP. Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta. J Immunol 1992;148:3768-75. 293. Jung S, Huitinga I, Schmidt B, Zielasek J, Dijkstra CD, Toyka KV, Hartung HP. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993;119:195-202. 294. Jung S, Hartung HP, Toyka KV. Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis. Ann Neurol 1993;34:113-4. 295. Jung S, Schluesener HJ, Toyka KV, Hartung HP. Modulation of EAE by vaccination with T cell receptor peptides: V beta 8 T cell receptor peptide-specific CD4+ lymphocytes lack direct immunoregulatory activity [published erratum appears in J Neuroimmunol 1994 Jan;49(1-2):222]. J Neuroimmunol 1993;45:15-22. 296. Jung S, Schluesener HJ, Schmidt B, Fontana A, Toyka KV, Hartung HP. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN. Immunology 1994;83:545-51. 297. Jung S, Toyka KV, Hartung HP. Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat. Clin Exp Immunol 1994;98:494-502. 298. Jung S, Schluesener HJ, Toyka KV, Hartung HP. Modulation of EAE by vaccination with T cell receptor peptides: V beta 8 T cell receptor peptide-specific CD4+ lack direct immunoregulatory activity. J Neuroimmunol 1994;49:222. 299. Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995;200:167-70. 300. Jung S, Donhauser T, Toyka KV, Hartung HP. Propentofylline and iloprost suppress the production of TNF-alpha by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmun 1997;10:519-29. 301. Jung S, Gaupp S, Hartung HP, Toyka KV. Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat. II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN. J Neuroimmunol 2001;116(1):21-8. 302. Kahl KG, Naumann M, Oertele E, Warmuth-Metz M, Toyka KV. Nervenarzt 1998;69:1115-22. 303. Kahl KG, Kruse N, Faller H, Weiß H, Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood correlates with depression scores in patients with multiple sclerosis. Psychoneuroendocrinology 2002;27:671-81. 304. Kahl KG, Kruse N, Toyka KV, Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J Neurol Sci 2002;200(1-2):53-5. 305. Kallmann B, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC, Rieckmann P. Characteristic gene expression profile of human cerebral endothelial cells. FASEB J 2002;16:589-591. 306. * Kamm C, Kastellon-Konkiewicz E, Naumann M, Dimova P, Nebe A, Ceballos-Baumann A, Gasser T. GAG deletion in the DYT1 gene in early limb-onset idiopathic torsion dystonia in Germany. Mov Disord 1999;14:681-683. 307. * Kamm C, Naumann M, Müller J, Mai N, Riedel L, Wissel J, Gasser T. The DYT1 GAG deletion is infrequent in sporadic and familial writer´s cramp. Mov Disord 2000;15:1238-1241. 308. * Kausch K, Müller CR, Grimm T, Ricker K, Rietschel M, Rudnik-Schoneborn S, et al. No evidence for linkage of autosomal dominant proximal spinal muscular atrophies to chromosome 5q markers. Hum Genet 1991;86(3):317-8. 309. * Keberle M, Jenett M, Kenn W, Reiners K, Peter M, Haerten R, Hahn D. Technical advances in ultrasound and MR imaging of carpal tunnel syndrome. Eur Radiol 2000;10:1043-50. 310. * Kessler KR, Schnitzler A, Classen J, Benecke R. Reduced inhibition within primary motor cortex in patients with poststroke focal motor seizures. Neurology 2002;59:1028-1033. 311. * Kiefer R, Supler ML, Toyka KV, Streit WJ. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive glial cells. Neurosci Lett 1994;166:161-4. 312. Kiefer R, Streit WJ, Toyka KV, Kreutzberg GW, Hartung HP. Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Int J Dev Neurosci 1995;13:331-9. 313. Kiefer R, Funa K, Schweitzer T, Jung S, Bourde O, Toyka KV, Hartung HP. Transforming growth factor-beta 1 in experimental autoimmune neuritis. Cellular localization and time course. Am J Pathol 1996;148:211-23. 314. Kiefer R, Schweitzer T, Jung S, Toyka KV, Hartung HP. Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. J Neuropathol Exp Neurol 1998;57:385-95. 315. Kiefer R, Kieseier BC, Bruck W, Hartung HP, Toyka KV. Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies [published erratum appears in Brain 1998 Jun;121(Pt 6):1190]. Brain 1998;121:469-79. 316. * Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Progr Neurobiol 2001;64:109-127. 317. Kiefer, G., Rieckmann, P. Neuritis nervi optici: Erster Hinweis auf eine Multiple Sklerose? Aktuelle diagnostische und therapeutische Strategien. Der Ophthalmologe 2001;98:310-318. 318. Kieseier BC, Hartung HP. Matrix metalloproteinases in experimental autoimmune encephalomyelitis. Adv Exp Med Biol 1997;421:303-6. 319. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GM, Schweitzer T, Gearing AJ, Hartung HP. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-66. 320. Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, Hartung HP. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-34. 321. * Kieseier BC, Schneider C, Clements JM, Gearing AJH, Gold R, Toyka KV, Hartung HP. Expression of specific matrix metalloproteinases in inflammatory myopathies. Brain 2001;124:341-351. 322. Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodroofe N, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002;125(Pt 4):823-34. 323. Kilo S, Schmelz M, Koltzenburg M, Handwerker HO. Different patterns of hyperalgesia induced by experimental inflammation in human skin. Brain 1994;117:385-396. 324. * Klein R, Müllges W, Bendszus M, Woydt M, Kreipe H, Roggendorf W. Primary intracerebral Hodgkin´s disease. Report of a case with Epstein-Barr Virus association, and review of the literature. Am J Surg Pathol 1999,23:477-81. 325. Kleopa K, Becker G, Roggendorf W, Reichmann H. Primary T-cell lymphoma of the cerebellum. A case report. J Neurooncol 1996;27:225-230. 326. Klopstock T, Naumann M, Schalke B, Bischof F, Seibel P, Kottlors M, Eckert P, Reiners K, Toyka KV, Reichmann H. Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA. Neurology 1994;44:862-6. 327. Klopstock T, Naumann M, Seibel P, Schalke B, Reiners K, Reichmann H. Mitochondrial DNA mutations in multiple symmetric lipomatosis. Mol Cell Biochem 1997;174:271-5. 328. * Knebusch M, Strassburg HM, Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998;40:631-9. 329. Kneip M, Ferbert A, Müllges W. Kongenitale horizontale Blickparese: Vier Fallbeschreibungen mit elektrookulographischen und MR-Untersuchungen. In: Schimrigk K, Haaß A, Hamannn G (Hrsg). Verhandlungen Deutsche Gesellschaft für Neurologie 7 1992;178-9. 330. Knieling J, Weiss H, Faller H, Lang H, Schalke B, Toyka K. Krankheitsverlauf bei Myasthenia gravis. Ergebnisse einer Langsschnittstudie zur Bedeutung psychosozialer Pradiktoren. Nervenarzt 1998;69:137-44. 331. * Kobelt G, Lindgren P, Smala A, Rieckmann P and the German Cost of MS Study Group. Costs and Quality of Life in Multiple Sclerosis. An observational study in Germany. Health Economics in Prevention and Care 2001;2:60-68. 332. Kobsar I, Mäurer M, Ott T, Martini R. Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32. Neurosci Lett 2002;320(1-2):17-20. 333. Kobsar I, Berghoff M, Samsam M, Wessig C, Mäurer M, Toyka KV, Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 2003;126(Pt 4):804-13. 334. * Koch MC, Ricker K, Otto M, Grimm T, Bender K, Zoll B, et al. Linkage data suggesting allelic heterogeneity for paramyotonia congenita and hyperkalemic periodic paralysis on chromosome 17. Hum Genet 1991;88(1):71-4. 335. * Koch MC, Ricker K, Otto M, Grimm T, Hoffman EP, Rudel R, et al. Confirmation of linkage of hyperkalaemic periodic paralysis to chromosome 17. J Med Genet 1991;28(9):583-6. 336. * Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257(5071):797-800. 337. * Koch MC, Ricker K, Otto M, Wolf F, Zoll B, Lorenz C, et al. Evidence for genetic homogeneity in autosomal recessive generalised myotonia (Becker). J Med Genet 1993;30(11):914-7. 338. * Koch MC, Baumbach K, George AL, Ricker K. Paramyotonia congenita without paralysis on exposure to cold: a novel mutation in the SCN4A gene (Val1293Ile). Neuroreport 1995;6(15):2001-4. 339. * Koch J, Strik WK, Becker T, Fleischer K, Gold R, Hofmann E. Akute korperlich begründbare Psychose nach Malaria tropica. Nervenarzt 1996;67:72-6. 340. Koehler MR, Bosserhoff A, von Beust G, Bauer A, Blesch A, Buettner R, Schlegel J, Bogdahn U, Schmid M. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 1996;35:265-7. 341. Kolb-Mäurer A, Kämmerer U, Mäurer M, Gentschev I, Bröcker E-B, Rieckmann P, Kämpgen E. Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol. Med Microbiol 2003;35:255-62. 342. * Koltzenburg M, Lundberg LER, Torebjörk HE. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 1992;51:207-219. 343. Koltzenburg M, Handwerker HO, Torebjörk HE. The ability of humans to localise noxious stimuli. Neurosci Lett 1993;150:219-22. 344. * Koltzenburg M, Torebjörk HE, Wahren LK. Nociceptor modulated central sensitization causes mechanical hyperalgesia in acute chemogenic and chronic neuropathic pain. Brain 1994;117:579-91. 345. * Koltzenburg M, Handwerker HO. Differential ability of human cutaneous nociceptors to signal mechanical pain and to produce vasodilatation. J Neurosci 1994;14:1756-65. 346. Koltzenburg M, Kees S, Budweiser S, Ochs G, Toyka KV. The properties of unmyelinated afferents change in a chronic constriction neuropathy. In: Gebhart GF, Hammond DL, Jensen TS (Hrsg). Proceedings of the VIIth World Congress on Pain. Seattle: IASP Press 1994;511-522. 347. * Koltzenburg M, Häbler HJ, Jänig W. Functional reinnervation of the vasculature of the adult cat paw pad by axons originally innervating vessels in hairy skin. Neuroscience 1995;67:245-52. 348. Koltzenburg M. The stability and plasticity of the encoding properties of peripheral nerve fibres and their relationship to provoked and ongoing pain. Semin Neurosci 1995;7:199-210. 349. Koltzenburg M, McMahon SB. Mechanically insensitive primary afferents innervating the urinary bladder. In: Gebhart GF (Hrsg). Visceral Pain. Seattle: IASP Press 1995;163-192. 350. Koltzenburg M, Torebjörk HE. Pain and hyperalgesia in acute inflammatory and chronic neuropathic conditions. Lancet 1995;345:1111. 351. * Koltzenburg M, Häbler H-J, Jänig W. Functional reinnervation of sweat glands in the adult cat paw by inappropriate postganglionic axons. J Auton Nerv Syst 1996;60:193-199. 352. Koltzenburg M. Afferent mechanisms mediating pain and hyperalgesia in neuralgia. In: Jänig W, Stanton-Hicks M (Hrsg). Reflex Sympathetic Dystrophy: A Reappraisal. Seattle: IASP Press 1996;123-150. 353. Koltzenburg M, Reiners K. Neuropathische Schmerzen: Pathophysiologie und Beurteilung. In: Suchenwirth RMA (Hrsg). Befund und Befinden. Stuttgart: G. Fischer Verlag 1997;7–15. 354. Koltzenburg M, Lewin GR. Der Einflu von Neurotrophinen auf den Phänotyp sensorischer Neurone. Neuroforum 1997;3:27-31. 355. Koltzenburg M, Lewin GR. Receptive properties of embryonic chick sensory neurons innervating skin. J Neurophysiol 1997;78:2560-8. 356. Koltzenburg M, Reiners K. Neuropathische Schmerzen: Pathophysiologie und Beurteilung. In: Suchenwirth R (Hrsg). Befund und Befinden: Neurologische Begutachtung bei inadequatem Organbefund. Stuttgart: Fischer Verlag 1997;7–15. 357. Koltzenburg M, Stucky CL, Lewin GR. Receptive properties of mouse sensory neurons innervating hairy skin. J Neurophysiol 1997;78:1841-50. 358. Koltzenburg M. The sympathetic nervous system and pain. In: Dickenson A, Besson J-M (Hrsg). The Pharmacology of Pain. Berlin: Springer Verlag 1997;61-91. 359. Koltzenburg M, Bergmann I, Petersen M. What is the potential of studying receptor expression on nociceptors? Pain Forum 1998;7:79-83. 360. Koltzenburg M. Painful neuropathies. Curr Opin Neurol 1998;11:515-21. 361. Koltzenburg M, Bennett DLH, Shelton DL, McMahon SB. Neutralisation of NGF prevents the sensitisation of nociceptors innervating inflamed skin. Eur J Neurosci 1999;11:1698-1704. 362. Koltzenburg M, Wall PD, McMahon SB. Does the right know what the left is doing? Trends Neurosci 1999;22:122-127. 363. Koltzenburg M. The changing sensitivity in the life of a sensory neuron. Pain 1999;Suppl. 6:S93- 364. * Kotitschke K, Schnackerz KD, Dringen R, Bogdahn U, Haase A, von Kienlin M. Investigation of the 1H NMR visibility of lactate in different rat and human brain cells. NMR Biomed 1994;7:349-55. 365. * Kotitschke K, Tonn JC, Goldbrunner R, Bogdahn U, Haase A. 1H NMR investigations of tumor spheroids grown from a human glioma biopsy or from a human malignant glioma cell line. J Magn Reson B 1995;109:39-43. 366. * Kress W, Mueller-Myhsok B, Ricker K, Schneider C, Koch MC, Toyka KV, Grimm T. Proof of genetic heterogenetiy in the proximal myotonic myopathy syndrome (PROMM) and ist relationship to myotonic dystrophy type 2 (DM2) Neuromus Disord 2000;10:478-480. 367. Krone A, Becker G, Koulis D, Lindner A, Roggendorf W, Bogdahn U, Hofmann E. Pre- and intraoperative transcranial color-coded real-time Sonography in stereotactic biopsies of midline tumors. Advances in Neurosurgery 1994;22:74-78. 368. Kruse N, Pette M, Toyka K, Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J Immunol Methods 1997;210:195-203. 369. Kruse N, Berg D, Francis MJ, Naumann M, Rausch WD, Reiners K, Rieckmann P, Weishaupt A, Becker G. Reduction od Menkes mRNA and copper in leucocytes of patients with primary adult-onset dystonia. Ann Neurol 2001;49:405-408. 370. Kruse N, Moriabadi N, Rieckmann P. Determination of early immunological responses in cultures of primary stimulated human peripheral mononuclear cells. J Immunol Methods 2001;247:131-1391. 371. * Kuepper T, Classen J. Single grand-mal seizures provoked by altitude. J Travel Med 372. * Küry P, Stoll G, Müller HW. Molecular mechanisms of cellular interactions in peripheral nerve regeneration. Curr Op Neurol 2001;14:635-639. 373. * Kunesch E, Reiners K, Müller-Mattheis V, Strohmeyer T, Ackermann R, Freund HJ. Neurological risk profile in organic erectile impotence. J Neurol Neurosurg Psychiatry 1992;55:275-81. 374. * Kunesch E, Classen J, Bettag M, Kahn T, Ulrich F, Bock WJ, Freund H-J, Seitz RJ. Representational cortical plasticity associated with brain tumours: evidence from Laser-induced interstitial thermotherapy. Acta Neurol Scand 2003; im Druck. 375. * Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P. Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994;43:183-201. 376. * Lange KW, Paul GM, Naumann M, Gsell W. Dopaminergic effects on cognitive performance in patients with Parkinson s disease. J Neural Trans 1995;46:423-432. 377. * Lange KW, Tucha O, Steupl A, Gsell W, Naumann M. Subjective time estimation in Parkinson s disease. J Neural Trans 1995;46:433-438. 378. * Lehmann-Horn F, Rudel R, Ricker K. Non-dystrophic myotonias and periodic paralyses. A European Neuromuscular Center Workshop held 4-6 October 1992, Ulm, Germany. Neuromuscul Disord 1993;3(2):161-8. 379. Lehrmann E, Kiefer R, Finsen B, Diemer NH, Zimmer J, Hartung HP. Cytokines in cerebral ischemia: expression of transforming growth factor beta-1 (TGF-beta 1) mRNA in the postischemic adult rat hippocampus. Exp Neurol 1995;131:114-23. 380. Lehrmann E, Kiefer R, Christensen T, Toyka KV, Zimmer J, Diemer NH, Hartung HP, Finsen B. Microglia and macrophages are major sources of locally produced transforming growth factor-beta1 after transient middle cerebral artery occlusion in rats. Glia 1998;24:437-48. 381. Leussink V, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leucocytes. Arch Neurol 2001;58:91-97. 382. Leussink VI, Zettl UK, Jander S, Pepinsky RB, Lobb RR, Stoll G, Toyka KV, Gold R. Blockade of signalling of the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T-cell apoptosis in sciatic nerve. Acta Neuropathol 2002;103:131-136. 383. * Lindberg RLP, Martini R, Baumgartner M, Erne B, Borg J, Zielasek J, Ricker K, Steck A, Toyka KV, Meyer UA. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 1999;103:1127-1134. 384. Lindenlaub T, Sommer C. Partial sciatic nerve transection as a model of neuropathic pain: a qualitative and quantitative neuropathological study. Pain 2000:89:97-106. 385. Lindenlaub T, Sommer C. Epidermal innervation density after partial sciatic nerve lesion and pain related behavior in the rat. Acta Neuropathol (Berl) 2002;104:137-143. 386. Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and non- inflammatory neuropathies. Acta Neuropathol 2003; im Druck. 387. Lindner A, Becker G, Warmuth-Metz M, Schalke BC, Bogdahn U, Toyka KV. Magnetic resonance image findings of spinal intramedullary abscess caused by Candida albicans: case report. Neurosurgery 1995;36:411-2. 388. Lindner A, Schneider C, Hofmann E, Soerensen N, Toyka KV. Isolated meningeal tuberculoma mimicking meningioma: case report. Surg Neurol 1995;43:81-3. 389. Lindner A, Becker G, Bogdahn U, Krone A, Becker T, Hofmann E. Stellenwert der transkraniellen farbkodierten Echtzeitsonographie in der Diagnostik zerebraler Lasionen. Nervenarzt 1995;66:252-60. 390. Lindner A, Reiners K, Toyka KV. Meningeal hyperperfusion visualized by MRI in a patient with visual hallucinations and migraine. Headache 1996;36:53-7. 391. Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol 1997;244:515-20. 392. Lindner A, Georgiadis D, Hofmann E, Becker G, Reiners K, Reichmann H. Ophthalmoplegia plus: clinical relevance of magnetic resonance tomogaphy findings. Eur J Med Res 1997;2:311-4. 393. Lindner A, Hofmann E, Naumann M, Becker G, Reichmann H. Clinical, morphological, biochemical, and neuroradiological features of mitochondrial encephalomyopathies. Presentation of 19 patients. Mol Cell Biochem 1997;174:297-303. 394. Lindner A, Shambal S, Georgiadis D, Becker G. Transkranielle farbkodierte Duplexsonographie in der interventionellen Therapie zerebraler Aneurysmen. Ultraschall Med 1997;18:148-152. 395. Lindner A, Georgiadis D, Gahn G, Becker G. Rest perfusion of coiled aneurysms detected by transcranial color-coded duplex sonography: initial results. Stroke 1997;28:1090-1091. 396. Linker RA, Gaupp S, Mäurer M, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002;8(6):620-624. 397. * Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293(5531):864-7. 398. * Logigian EL, Hefter HH, Reiners K, Freund HJ. Neurophysiology of fastest voluntary muscle contraction in hereditary neuropathy. Ann Neurol 1990;27:3-11. 399. * Logigian E, Hefter H, Reiners K, Freund HJ. Does tremor pace repetitive voluntary motor behavior in Parkinson's disease? Ann Neurol 1991;30:172-9. 400. Mäurer M, Shambal S, Berg D, Woydt M, Hofmann E, Georgiadis D, Lindner A, Becker G. Differentiation between intracerebral hemorrhage and ischemic stroke by transcranial color-coded duplex-sonography. Stroke 1998;29:2563-7. 401. Mäurer M, Lindner A., Becker G. Liquorzirkulationsstörungen. In: Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;323-331. 402. Mäurer M, Müllges W, Becker G. Diagnosis of MCA-occlusion and monitoring of systemic thrombolytic therapy with contrast enhanced Transcranial Duplex sonography. J Neuroimaging 1999;9:99-101. 403. Mäurer M, Sommer C. POEMS-Syndrom - ungewöhnliche Manifestation mit beidseitigem Charcot-Gelenk. Dbd med Wschr 1999;124:346-350. 404. Mäurer M, Becker G, Wagner R, Woydt M, Hofmann E, Lindner A, Krone A. Postoperative imaging of residual tumor mass in high grade gliomas and ist relevance for patients survival. Acta Neurochir 2000;142:1089-1097. 405. Mäurer M, Gold R, Toyka KV, Rieckmann P. Behandlung der schubförmigen multiplen Sklerose mit rekombinanten Interferon-beta Präparaten. Aspekte zur Pharmakologie und Dosierung. Nervenarzt 2001;72:108-116. 406. Mäurer M, Schmid CD, Bootz F, Zielasek J, Toyka KV, Oehen S, Martini R. Bone marrow transfer from wild-type mice reverts the beneficial effect of genetically mediated immune deficiency in myelin mutants. Mol Cell Neurosci 2001;17(6):1094-1101. 407. Mäurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002;15:617-622. 408. Mäurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R. Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 2002;200(4):405-14. 409. Mäurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8. 410. Mäurer M, Ponath A, Kolb-Mäurer A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human CTLA-4 gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8. 411. Mäurer M, Ponath A, Kruse N, Rieckmann P. CTLA4 exon 1 dimorphism is associated with primary progressive multiple sclerosis. Neuroimmunol 2002;131:213-215. 412. Mäurer M, Schließer M, Becker G, Rieckmann P. The role of transcranial ultrasoundin multiple sclerosis. Internat MS Journal 2002;9:37-41. 413. Mäurer M, Rieckmann P. Ansätze zur Neuroprotektion bei Multipler Sklerose. Nervenheilkunde 2002;21:512-516. 414. Mäurer M, Toyka KV, Gold R. Immune mechanisms in acquired demyelinating neuropathies: lessons from animal models. Neuromuscul Disord 2002;12(4):405-414. 415. Mäurer M, Müller M, Kobsar I, Leonhard C, Martini R, Kiefer R. Origin of pathogenic macrophages and endoneurial fibroblast-like cells in an animal model of inherited neuropathy. Mol Cell Neurosci 2003; im Druck. 416. * Magerl W, Koltzenburg M, Meyer-Jürgerns D, Handwerker HO. Somatotopic organization of nociceptor-induced vascular response pattern reflect central nociceptive processings in humans. In: Gebhart GF, Hammond DL, Jensen TS (Hrsg). Proceedings of the VIIth World Congress on Pain. Seattle: IASP Press 1994;843-856. 417. * Magerl W, Koltzenburg M, Schmitz J, Handwerker HO. Asymetry and time course of cutaneous sympathetic reflex responses following sustained excitation of chemosensitive nociceptors in humans. J Auton Nerv Syst 1996;57:63-72. 418. Magnus T, Chan A, Grauer O, Toyka KV, Gold R. Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J Immunol 2001;167(9):5004-10. 419. Magnus T, Beck M, Gieß R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25(5):709-714. 420. Magnus T, Chan A, Linker RA, Toyka KV, Gold R. Astrocytes are less efficient in the removal of apoptotic lymphocytes than microglia cells: implications for the role of glial cells in the inflamed central nervous system. J Neuropathol Exp Neurol 2002;61(9):760-6. 421. Magnus T, Chan A, Savill J, Toyka KV, Gold R. Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system (CNS) by microglial cells and its functional implications. J Neuroimmunol 2002;130(1-2):1-9. 422. * Magyar JP, Martini R, Ruelicke T, Aguzzi A, Adlkofer K, Dembic Z, Zielasek J, Toyka KV, Suter U. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 1996;16:5351-60. 423. Mang S, Weiss H, Schalke B. Psychosomatische und somatopsychische Aspekte der Myasthenia gravis. Ein kritischer Literaturuberblick. Z Klin Psychol Psychopathol Psychother 1993;41:69-86. 424. * Martin R, Meinck HM, Schulte-Mattler W, Ricker K, Mertens HG. Borrelia burgdorferi myelitis presenting as a partial stiff man syndrome. J Neurol 1990;237(1):51-4. 425. Martin R, Schwulera U, Menke G, Rudolph W, Buch K, Fasold H, Lissner R, Thrun A, Krauseneck P, Bogdahn U. Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration. Eur Cytokine Netw 1992;3:399-406. 426. Martini R, Xin Y, Schmitz B, Schachner M. The L2/HNK-1 Carbohydrate Epitope is Involved in the Preferential Outgrowth of Motor Neurons on Ventral Roots and Motor Nerves. Eur J Neurosci 1992;4(7):628-639. 427. Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet 1995;11:281-6. 428. Martini R, Schachner M. Molecular bases of myelin formation as revealed by investigations on mice deficient in glial cell surface molecules. Glia 1997;19:298-310. 429. Martini R. Animal models for inherited peripheral neuropathies. J Anat 1997;191:321-36. 430. Martini R. IG-Superfamily molecules in myelination and regeneration in the peripheral nervous system In: P. Sonderegger, Immunglobulin superfamily molecules in neural development, regeneration, and disease 1998;261-285. 431. Martini R, Zielasek J, Toyka KV. Inherited demyelinating neuropathies: from gene to disease. Curr Opin Neurol 1998;11:545-56. 432. Martini R, Carenini S. Formation and maintenance of the myelin sheath in the peripheral nerve: roles of cell adhesion molecules and the gap junction protein connexin 32. Microsc Res Tech 1998;41:403-15. 433. Martini R. Introduction to myelin formation and maintenance. Microsc Res Tech 1998;41:341-3. 434. Martini R. P0-deficient knock-out mice as tools to understand pathomechanisms in Charcot- Marie-Tooth 1B and P0-related Déjérine-Sottas-Syndrome. Ann N Y Acad Sci 1999;883:273-280. 435. Martini R. Animal models for inherited peripheral neuropathies: chances to find treatment strategies? J Neurosci Res 2000;61:244-250. 436. Martini R. The effect of myelinating Schwann cells on axons. Muscle Nerve 2001;24(4):456-466. 437. Martini R, Berciano J, Van Broeckhoven C. 5th Workshop of the European CMT consortium, 69th ENMC International Workshop: "Therapeutic approaches in CMT neuropathies and related disorders", 23-25th April 1999, Soestduinen, The Netherlands. Neuromusc Dis 2002;10:69-74. 438. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, Filippi M. Inflammation in multiple sclerosis: the good, the bad and the complex. Lancet Neurology 2002;1:499-509. 439. * Marx A, O'Connor R, Geuder KI, Hoppe F, Schalke B, Tzartos S, Kalies I, Kirchner T, Müller- Hermelink HK. Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas. Lab Invest 1990;62:279-86. 440. * Marx A, Kirchner T, Greiner A, Müller-Hermelink HK, Schalke B, Osborn M. Neurofilament epitopes in thymoma and antiaxonal autoantibodies in myasthenia gravis. Lancet 1992;339:707-8. 441. * Marx A, Osborn M, Tzartos S, Geuder KI, Schalke B, Nix W, Kirchner T, Müller-Hermelink HK. A striational muscle antigen and myasthenia gravis-associated thymomas share an acetylcholine-receptor epitope. Dev Immunol 1992;2:77-84. 442. * Marx A, Kirchner T, Greiner A, Schalke B, Müller-Hermelink HK. Neurofilament Expression in epithelialen Thymustumoren und antiaxonale Autoantikorper bei Myasthenia gravis: ein Modell fur Autoimmunität durch defekte T-Zell-Selektion. Verh Dtsch Ges Pathol 1992;76:256-61. 443. * Marx A, Kirchner T, Greiner A, Schalke B, Müller-Hermelink HK. Myasthenia gravis-associated thymic epithelial tumors express neurofilaments and are associated with antiaxonal autoimmunity. Ann N Y Acad Sci 1993;681:107-9. 444. McMahon SB, Koltzenburg M. Itching for an explanation. Trends Neurosci 1992;15:497-501. 445. McMahon SB, Koltzenburg M. Changes in the afferent innervation of the inflamed urinary bladder. In: Mayer EA, Raybould HE (Hrsg). Basic and Clinical Aspects of Chronic Abdominal Pain. Amsterdam: Elsevier 1993b:151-175. 446. McMahon SB, Koltzenburg M. Nocicptors, novel types. In: Adelman G, Smith B (Hrsg). Neuroscience Year: Supplement to the Encyclopedia of Neuroscience 3. Boston: Birkhäuser 1993a:103-105. 447. McMahon SB, Koltzenburg M. Silent afferents and visceral pain. In: Fields HL, Liebeskind JC (Hrsg). Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Seattle: IASP Press 1994;11-30. 448. McMahon SB, Dmitrieva N, Koltzenburg M. Visceral pain. Br J Anaesth 1995;75:132-144. 449. McMahon SB, Bennett DLH, Koltzenburg M. The biological effects of nerve growth factor on primary sensory neurones. In: Borssok M (Hrsg). Molecular neurobiology of pain. Seattle: IASP Press 1997;59-78. 450. McMahon SB, Koltzenburg M, Wall PD. Does the right know what the left is doing? Trends in Neuroscience 1999;22:122-127. 451. * Meinck HM, Ricker K, Hulser PJ, Schmid E, Peiffer J, Solimena M. Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol 1994;241(3):157-66. 452. * Meinck HM, Ricker K, Hulser PJ, Solimena M. Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 1995;242(3):134-42. 453. * Meixensberger J, Caffier H, Naumann M, Hofmann E. Sex hormone binding and peritumoural oedema in meningiomas: is there a correlation? Acta Neurochir (Wien) 1992;115:98-102. 454. * Melms A, Weissert R, Klinkert WE, Schalke BC, Tzartos S, Wekerle H. Specific immune complexes augment in vitro acetylcholine receptor- specific T-cell proliferation. Neurology 1993;43:583-8. 455. * Menge T, Jander S, Stoll G. Induction of the proinflammatory cytokine interleukin-18 by axonal injury. J Neurosci Res 2001;65:332-339. 456. Metzger F, Wiese S, Sendtner M. Effect of glutamate on dendritic growth in embryonic rat motoneurons. J Neurosci 1998;18:1735-42. 457. Meurers B, Kohlhepp W, Gold R, Rohrbach E, Mertens HG. Histopathological findings in the central and peripheral nervous systems in neuroborreliosis. A report of three cases. J Neurol 1990;237:113-6. 458. Meyding Lamadé U, Müllges W, Bogdahn U. Akute Virusinfektionen des ZNS und chronische Meningoencephalitiden. In: Schwab S, Krieger D, Müllges W, Hamann GF, Hacke W (Hrsg). Neurologische Intensivmedizin, Springer 1999. 459. * Meyer-Kleine C, Ricker K, Otto M, Koch MC. A recurrent 14 bp deletion in the CLCN1 gene associated with generalized myotonia (Becker). Hum Mol Genet 1994;3(6):1015-6. 460. * Meyer-Kleine C, Steinmeyer K, Ricker K, Jentsch TJ, Koch MC. Spectrum of mutations in the major human skeletal muscle chloride channel gene (CLCN1) leading to myotonia. Am J Hum Genet 1995;57(6):1325-34. 461. Michel U, Kallmann B, Rieckmann P, Isbrandt D. UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum. RNA 2002;8:1538-47. 462. Moore AP, Naumann M (Hrsg). Handbook of botulinum toxin treatment. Blackwell Science, 463. Moriabadi NF, Niewiesk S, Kruse N, Jung S, Weissbrich B, ter Meulen V, Toyka KV, Rieckmann P. Influenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 2001;56(7):938-43. 464. Morrissey SP, Deichmann R, Syha J, Simonis C, Zettl U, Archelos JJ, Jung S, Stodal H, Lassmann H, Toyka KV, Haase A, Hartung HP. Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico- histological and MRI studies. J Neuroimmunol 1996;69:85-93. 465. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, Lassmann H, Hartung HP, Haase A, Toyka KV. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996;119:239-48. 466. * Moxley RT, 3rd, Ricker K, Kingston WJ, Bohlen R. Potassium uptake in muscle during paramyotonic weakness. Neurology 1989;39(7):952-5. 467. * Moxley RT, 3rd, Ricker K. Proximal myotonic myopathy. Muscle Nerve 1995;18(5):557-8. 468. * Moxley RT, 3rd, Udd B, Ricker K. Proximal myotonic myopathy (PROMM) and other proximal myotonic syndromes. Neuromuscul Disord 1998;8(7):519-20. 469. Müller B, Adelt K, Reichmann H, Toyka K. Atraumatic needle reduces the incidence of post- lumbar puncture syndrome. J Neurol 1994;241:376-80. 470. * Müller-Felber W, Ansevin CF, Ricker K, Müller-Jenssen A, Topfer M, Goebel HH, et al. Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis. Neuromuscul Disord 1999;9(8):604-7. 471. Müllges W, Naumann M, Reichmann H. Is chronic dermato- or polymyositis misdiagnosed as "weakness of old age"? Dtsch Med Wochenschr 1993;118:1520-4. 472. Müllges W, Weiller C, Leibold M, Ringelstein EB. Non-invasive diagnosis of internal carotid artery dissections. J Neurol Neurosurg Psychiatr 1992;55:95-104. 473. Müllges W, Ferbert A. Congenital bilateral horizontal gaze palsy in two adult patients. Neuroophthalmology 1992;12:115-9. 474. Müllges W, Dorn T, Reichmann H. A case of myoclonus epilepsy and lactic acidosis: difficulties in diagnosis and treatment of terminal mitochondrial cytopathy. Intensive Care Medicine 1994;613- 4. 475. Müllges W. Aktuelle Therapiekonzepte bei ischämischen Insulten. Psycho 1994;20:99-103. 476. Müllges W, Schmitt-Rotte H. Infektionsprophylaxe bei Dauerverweilkanülen. Dtsch Med WSchr 477. Müllges W. Zerebrale Perfusionsstörungen beim älteren Menschen als Notfall. In: Sefrin P (Hrsg). Der ältere Mensch als Notfallpatient. Klinische und experimentelle Notfallmedizin 15. Zuckschwerdt, München 1994;84-88. 478. Müllges W, Sporkert U, Weilbach FX, Moldenhauer G, Steinke E. Einfluß allgemeiner Maßnahmen auf die Komplikationsrate in der Frühphase nach Subarachnoidalblutung. In: Jerusalem F, Ries F (Hrsg). Verhandlungen der Deutschen Gesellschaft für Neurologie 8, Springer, Berlin, 1994; 419-20. 479. Müllges W, Toyka KV, Hartung HP. Acute muscular weakness. In: Hacke W, Hanley DF, Einhäupl KM, Bleck TP, Diringer MN (Hrsg). Neurocritical Care. Springer Verlag, Heidelberg, 1994;307-318. 480. Müllges W. Zerebrale Perfusionsstörungen beim älteren Menschen als Notfall. Z. Leben retten 481. Müllges W. Pathophysiologie und Klinik der Beatmung. In: Diener HC, Felgenhauer K, Wallesch CW (Hrsg). Neurologie 96 1996;Bd 3:9-15. 482. Müllges W, Toyka KV. Differenzierte Immuntherapie bei neuromuskulären Krankheiten. In: Diener HC, Felgenhauer K, Reichmann H, Wallesch CW, Wiegand F (Hrsg). Akt Neurol 1997, Thieme, Stuttgart 1997;Bd 3:1-10. 483. Müllges W, Toyka KV. Akute Muskelschwäche - Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 1997;34:110- 23. 484. Müllges W. Frühe und längerfristige neuropsychologische Veränderungen nach aortokoronarer Bypass-Operation. Kardiotechnik 1999;8:93-99. 485. Müllges W, Berg D, Babin-Ebell J, Toyka KV, Elert O. Cerebral microembolus generation in different extracorporal circulation systems. Cerebrovasc Dis 1999;9:265–9. 486. Müllges W, Berg D, Toyka KV. Bilateral cerebral emboli monitoring during extracorporeal circulation. Ultrasound Med Biol 1999;25:755-758. 487. Müllges W, Berg D, Schmidtke A, Weinacker B, Toyka KV. Early natural course of transient encephalopathy after coronary artery bypass grafting. Crit Care Med 1999;28:1808-11. 488. Müllges W. Hypoxisch-ischämische und septische Encephalopathie. J Anästh Intensivbehandl 489. Müllges W, Franke D, Meixensberger J. Zur Dfferentialdiagnose des Alkoholentzugsanfalls: Subarachnoidalblutung. Intensivmed und Notfallmed 2000,37:44-7. 490. Müllges W. Hypoxisch-ischämische Encephalopathie. In: Noth J, Diener HC, Felgenhauer K, Wallesch CW, Busch E (Hrsg). Neurologie 2001, Thieme, Stuttgart 2001;127-129. 491. Müllges W. Nichtinvasive Beatmung bei neurologischen Intensivpatienten. Intensivmedizin und Notfallmedizin 38, 2001;1:49-53. 492. Müllges W, Franke D, Reents W, Babin-Ebell J. Brain microembolic counts during extracorporeal circulation depend on aortic cannula position. Ultrasound Med Biol 2001;27:933-6. 493. Müllges W, Misoph M, Berg D, Hickethier T, Babin-Ebell J. Einfluß verschiedener Aprotinin- Dosierungen auf die kognitive Leistung nach aortokoronarer Bypass-Chirurgie. Z Herz-Thorax-GefäßChir 2001;15:29-34. 494. Müllges W, Steinke E, Moldenhauer G, Berens N. Praxis medizinischer Thromboseprophylaxestrümpfe auf konservativen Intensivstationen in Deutschland. Dtsch Med Wschr 2001;126: 867-71. 495. Müllges W, Babin-Ebell J, Reents W, Toyka KV. Cognitive performance after coronary artery bypass grafting: a follow-up study. Neurology 2002;59(5):741-3. 496. Müllges W, Schneider C. Myasthenie, Botulismus, Organophosphate: Störungen der Neuromuskulären Endplatte. J Anästh Intensivbehandl 2002;9:51-53. 497. Müllges W, Stoll G. Hypoxisch-ischämische Encephalopathie. Akt Neurol 2002;29:431-446. 498. Müllges W. Was tun, wenn der Patient nicht wach wird? J Anästh Intensivbehandlung 2003; 499. Müllges W, Franke D, Reents R, Babin-Ebell J, Toyka KV. Reduced microembolism by optimized aortic cannula position does not gravely affect early postoperative brain dysfunction in CABG patients. Cerebrovasc Dis 2003;15(3):192-8. 500. Müllges W, Gold G. Myasthene Krise. Intensivmed und Notfallmedizin 2003; im Druck. 501. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 1999;70:371-386. 502. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) Immunmodulatorische Stufentherapie der multiplen Sklerose – 1. Ergänzung Dezember 2000. Der Nervenarzt 2001;79:130-139. 503. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) Immunmodulatorische Stufentherapie der multiplen Sklerose – 1. Ergänzung Dezember 2000. Der Nervenarzt 2001;72:150-157. 504. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). Immunmodulatorische Stufentherapie der multiplen Sklerose – neue Aspekte und praktische Umsetzung März 2002. Der Nervenarzt 2002;73:556-563. 505. Naumann M, Meixensberger J. Factors influencing meningioma recurrence rate. Acta Neurochir (Wien) 1990;107:108-11. 506. Naumann M, Toyka KV, Goebel HH, Hofmann E, Reichmann H. Focal myositis of the temporal muscle. Muscle Nerve 1993;16:1374-6. 507. Naumann M, Reiners K, Schalke B, Schneider C. Hyperkalaemia mimicking acute Guillain- Barré syndrome. J Neurol Neurosurg Psychiatry 1994;57:1436-7. 508. Naumann M, Supprian T, Kornhuber J, Lange KW, Reiners K. Bipolar affective psychosis after vigabatrin. Lancet 1994;343:606-7. 509. Naumann M, Schalke B, Klopstock T, Reichmann H, Lange KW, Wiesbeck G, Toyka KV, Reiners K. Neurological multisystem manifestation in multiple symmetric lipomatosis: a clinical and electrophysiological study. Muscle Nerve 1995;18:693-8. 510. Naumann M, Dauphin M, Reichmann H, Reiners K. Botulinum toxin in the management of paradoxical activity of jaw muscles. J Neurol Neurosurg Psychiatry 1995;59:192-3. 511. Naumann M, Reiners K, Gold R, Schindler R, Paulus W, Klopstock T, Reichmann H. Mitochondrial dysfunction in adult-onset myopathies with structural abnormalities. Acta Neuropathol (Berl) 1995;89:152-7. 512. Naumann M, Becker G, Toyka KV, Supprian T, Reiners K. Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology 1996;47:1284-90. 513. Naumann M, Reichmann H, Goebel HH, Moll C, Toyka KV. Glucocorticoid-sensitive hereditary inclusion body myositis. J Neurol 1996;243:126-30. 514. Naumann M, Reiners K. Diagnostic value of in situ muscle fiber conduction velocity measurements in myopathies. Acta Neurol Scand 1996;93:193-7. 515. Naumann M, Götz M, Reiners K, Lange KW, Riederer P. Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5- HIAA levels as evidence of impaired serotonergic metabolism. J Neural Transm 1996;103:1083-91. 516. Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997;42:973-5. 517. Naumann M, Kiefer R, Toyka KV, Sommer C, Seibel P, Reichmann H. Mitochondrial dysfunction with myoclonus epilepsy and ragged-red fibers point mutation in nerve, muscle, and adipose tissue of a patient with multiple symmetric lipomatosis. Muscle Nerve 1997;20:833-9. 518. Naumann M, Flachenecker P, Br¸cker EB, Toyka KV, Reiners K. Botulinum toxin for palmar hyperhidrosis. Lancet 1997;349:252. 519. Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brücke T. [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 1997;12:448-51. 520. Naumann M, Reiners K. Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain 1997;120:409-16. 521. Naumann M. Dystonien - ein häufig verkanntes Krankheitsbild. Allgemeinarzt 1997;1480-1485. 522. Naumann M. Botulinumtoxin - Wirkprinzip und klinische Anwendung. UniMed Verlag, Bremen 523. Naumann M. Wirkmechanismus und therapeutische Anwendungsmöglichkeiten von Botulinumtoxin. Med Welt 1998;49:388-391. 524. Naumann M, Bergmann I, Hofmann U, Hamm H, Reiners K. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements of application. Br J Dermatol 1998;139:1123-24. 525. Naumann M, Hofmann E, Toyka KV. Multifocal brain MRI hypointensities secondary to embolic metal fragments from a mechanical heart valve prosthesis: a possible source of epileptic seizures. Neurology 1998;51:1766-7. 526. Naumann M, Toyka KV, Mansouri Taleghani B, Ahmadpour J, Reiners K, Bigalke H. Depletion of neutralising antibodies resensitises a secondary non- responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiatry 1998;65:924-7. 527. Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301-4. 528. Naumann M, Bergmann I, Hofmann U, Hamm H, Reiners K. Botulinum toxin for focal hyperhidrosis: technical considerations and improvements in application. Br J Dermatol 1998;139:1123-4. 529. Naumann M, Warmuth-Metz M, Hillerer C, Solymosi L, Reiners K. 1H magnetic resonance spectroscopy of the lentiform nucleus in primary focal hand dystonia. Mov Disord 1998;13:929-33. 530. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brucke T. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord 1998;13:319-23. 531. Naumann M. Die Behandlung von Dystonien. In: Riederer, Laux, Pöldinger (Hrsg). Neuro- Psychopharmakologie. 2. Auflage, Springer Verlag Wien, New York 1999;422-438. 532. Naumann M. Dystonien. In: Reichmann H (Hrsg). Neurodegenerative Erkrankungen. UniMed Verlag Bremen 1999;50-64. 533. Naumann M. Konservative Therapie von Muskeldystrophien. Nervenheilkunde 1999. 534. Naumann M. Lipomatosen. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg). Neurologie in Praxis und Klinik. 3. Auflage, Thieme-Verlag Stuttgart - New York, 1999;924-927. 535. Naumann M. Rhabdomyolyse und Myoglobinurie. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg). Neurologie in Praxis und Klinik. 3. Auflage, Thieme-Verlag Stuttgart - New York 1999;611-613. 536. Naumann M. Therapie fokaler Hyperhidrosen mit Botulinumtoxin A. Dt Derm 1999;47:115-116. 537. Naumann M, Jost W, Toyka K. Botulinumtoxin in the treatment of neurological autonomous disorders. Arch Neurol 1999;56:914-916. 538. Naumann M, Reiners K. Botulinum toxin type A in the treatment of axillary, palmar, and other forms of focal hyperhidrosis. Eur J Neurol 1999;139:1123-4. 539. Naumann M, Lowe N, for the hyperhidrosis study group. A randomized, placebo-controlled, double-blind study of botulinum toxin type A in bilateral axillary hyperhidrosis. BMJ 2001;323:596-599. 540. Naumann M. Treatment of focal hyperhidrosis with botulinum toxin A. In: Brin MF, Hallett M, Jankovic J (Hrsg). Lippincott Williams & Wilkins, Philadelphia 2002;303-308. 541. Naumann M, Hamm H. Treatment of axillary hyperhidrosis. Br J Surg 2002;89:259-261. 542. Naumann M, Hamm H, Lowe N. Effect of Botulinum Toxin Type A on Quality of Life Measures in Patients With Excessive Axillary Sweating: A Randomized Controlled Trial. Br J Dermatol 2002;147:1218-1226. 543. Naumann M, Yakovleff A, Durif F. A randomized, double-blind, crossover comparison of the safety and efficacy of original BOTOX (botulinum toxin type A) in the treatment of cervical dystonia. J Neurol 2002;249:57-63. 544. Naumann M. Botulinumtoxin - Wirkprinzip und klinische Anwendung. 2. Auflage, UniMed Verlag, Bremen 2003. 545. Naumann M. Dystonien. In: Reichmann H (Hrsg). Neurodegenerative Erkrankungen. 2. Auflage, UniMed Verlag, Bremen 2003. 546. Naumann M. Dystonien: Eine sensomotorische Erkrankung. DNP 2003; im Druck. 547. Naumann M. Hypersecretory disorders. In: Moore AP, Naumann M (Hrsg). Handbook of botulinum toxin. Blackwell Science, Oxford 2003;343-359. 548. Naumann M, Abele-Horn M. Tetanus. Intensivmedizin 2003; im Druck. 549. Naumann M, Herting B. Treatment of pain in focal dystonia. In: Jost W (Hrsg).Botulinum toxin in painful diseases. Karger Verlag Basel 2003;1-13. 550. Naumann M, Jost W. Botulinum toxin treatment of secretion disorders. Mov Disord 2003; im 551. Naumann M, Lowe NJ, Kumar CR, Hamm H. Botulinum toxin type A is a safe and effective long-term treatment for axillary hyperhidrosis: a prospective study. Arch Dermatol 2003; im Druck. 552. Naumann M, Moore AP. Long-term safety of botulinum toxin A. Mov Disord 2003; im Druck. 553. Naumann M, Toyka KV, Moore AP. History and current application of botulinum toxin - from poison to remedy. In: Moore AP, Naumann M (Hrsg). Handbook of botulinum toxin. Blackwell Science, Oxford 2003;3-8. 554. * Nelles E, Butzler C, Jung D, Temme A, Gabriel HD, Dahl U, Traub O, Stumpel F, Jungermann K, Zielasek J, Toyka KV, Dermietzel R, Willecke K. Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci U S A 1996;93:9565-70. 555. * Nenninger R, Schultz A, Hoffacker V, Helmreich M, Wilisch A, Vandekerckhove B, Hünig T, Schalke B, Schneider C, Tzartos S, Kalbacher H, Müller-Hermelink HK, Marx A. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998;78:743-53. 556. * Neuberg D H-H, Carenini S, Schachner M, Martini R, Suter U. Accelerated demyelination of peripheral nerves in mice deficient in connexin 32 and protein zero. J Neurosci Res 1998;53:542-550. 557. Ochs G. Intrathecal baclofen. Baillieres Clin Neurol 1993;2:73-86. 558. Ochs G, Loew M, Tonn J, Toyka K. Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. Acta Anaesthesiol Scand 1998;42:786-93. 559. Ochs G, Penn RD, York M, Gieß R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(3):201-6. 560. Offenhäusser M, Herr AS, Hartkamp J, Wauben M, Magnus T, Grauer O, Seubert S, Weishaupt A, Toyka KV, Gold R, Troppmair J. Truncation of the neuritogenic peptide bP2(60-70) results in the generation of altered peptide ligands with the potential to interfere with T cell activation. J Neuroimmunol 2002;129(1-2):97-105. 561. Palmowski A, Reichmann H, Toyka KV. Neurofibromatous neuropathy. Muscle Nerve 562. * Pedrosa GF, Schneider C, Grohmann R, Rüther E. Unverträglichkeit von Olanzapin und Amisulprid bei multisystemischer myotoner Myopathie. Nervenarzt 2001:72;729-733. 563. Petersen M, Segond von Banchet G, Heppelmann B, Koltzenburg M. Nerve growth factor regulates the expression of bradykinin binding sites on adult sensory neurons via the neurotrophin receptor p75. Neuroscience 1998;83:161-8. 564. Pette M, Liebert UG, Gobel U, Grosse-Wilde H, Hartung HP, Toyka KV. Measles virus-directed responses of CD4+ T lymphocytes in MS patients and healthy individuals. Neurology 1993;43:2019-25. 565. Pette M, Hartung HP, Toyka KV. Die immunaugmentative Therapie (IAT) als Behandlung der Multiplen Sklerose. Warnung vor einer potentiell gesundheitsschädlichen Außenseitermethode. Nervenarzt 1994;65:878-90. 566. Pette M, Linington C, Gengaroli C, Grosse-Wilde H, Toyka KV, Hartung HP. T lymphocyte recognition sites on peripheral nerve myelin P0 protein. J Neuroimmunol 1994;54:29-34. 567. Pette M, Gengaroli C, Hartung HP, Greiner A, Giegerich G, Toyka KV. Human T lymphocytes distinguish bovine from human P2 peripheral myelin protein: implications for immunological studies on inflammatory demyelinating neuropathies. J Neuroimmunol 1994;52:47-52. 568. Pette M, Hartung HP, Toyka KV. Cyclophosphamid in der Therapie der chronisch-progredienten Multiplen Sklerose. Kritische Analyse der vorliegenden Studien. Nervenarzt 1994;65:271-4. 569. Pette M, Gold R, Pette DF, Hartung HP, Toyka KV. Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology 1995;30:59-69. 570. * Pohl-Koppe A, Dahm C, Kuhn JE, Hamann J, Fuhrmeister U, Gabriel M, Grüninger W, Metze H, Ranke M, Toyka K, et al. Neue Aspekte in der Diagnostik der Herpes-simplex-Virusenzephalitis - Fallberichte und virologische Befunde. Nervenarzt 1992;63:495-50. 571. Pollard JD, Westland KW, Harvey GK, Jung S, Bonner J, Spies JM, Toyka KV, Hartung HP. Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1995;37:467-75. 572. * Poot M, Hoehn H, Bogdahn U, Otto F. Bromodeoxyuridine hypersensitivity of metastatic melanoma cells. Melanoma Res 1992;2:241-6. 573. Preibisch M, Berg D, Hofmann E, Solymosi L, Naumann M. Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. J Neurol 2001;248:10-17. 574. Previtali SC, Archelos JJ, Hartung HP. Modulation of the expression of integrins on glial cells during experimental autoimmune encephalomyelitis. A central role for TNF-alpha. Am J Pathol 1997;151:1425-35. 575. Previtali SC, Archelos JJ, Hartung HP. Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1998;44:611-21. 576. PRISMS Study Group and UBC MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001;56:1628-1636. 577. Puls I, Becker G, Mäurer M, Müllges W. Cerebral arteriovenous transit time (cTT): a sonographic assessment of cerebral microcirculation. Ultrasound Med Biol 1999;25:503-7. 578. Quasthoff S, Sommer C. Pain Mechanisms in Nerve Injury: Peripheral Mechanisms, in Pain in peripheral nerve disease, vol 13. Edited by Sommer C. Basel, Karger, 2001, pp 110-148. 579. * Reents W, Müllges W, Franke D, Babin-Ebell J, Elert O. Regional cerebral oxygen saturation assessed by near-infrared spectroscopy during coronary artery bypass grafting with cardiopulmonary bypass and early postoperative cognitive function. In: Lewis BS, Halon DA, Flugelman MY, Hradec J (Hrsg). Advances in coronary artery disease. Monduzzi-Medimont, Bologna, 2001;747-53. 580. Reents W, Müllges W, Babin-Ebell J. Cerebral perfusion and cognitive function (Reply) Ann Thorac Surg 2002;75:10. 581. Reents W, Müllges W, Franke D, Babin-Ebell J, Elert O. Cerebral oxygen saturation assessed by near-infrared spectroscopy during coronary artery bypass grafting with cardiopulmonary bypass and early postoperative cognitive function. Ann Thorac Surg 2002;74:109-14. 582. Reents W, Müllges W, Franke D, Weigl A, Hopp H, Apfel CC, Babin-Ebell J, Elert O. Reduktion zerebraler Mikroembolien durch Positionierung der aortalen Kanüle in der Aorta deszendens. Kardiotechnik 2002;11:41-44. 583. Reichmann H, Gold R, Lestienne P, Meurers B. Das mitochondriale Genom und seine Deletionen als Krankheitsursache. Dtsch Med Wochenschr 1990;115:980-3. 584. Reichmann H, Gold R. Myopathies and cardiomyopathies: histochemical and biochemical analyses. Eur Heart J 1991;12 Suppl D:169-70. 585. Reichmann H, Degoul F, Gold R, Meurers B, Ketelsen UP, Hartmann J, Marsac C, Lestienne P. Histological, enzymatic and mitochondrial DNA studies in patients with Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia. Eur Neurol 1991;31:108-13. 586. Reichmann H, Gold R, Meurers B, Naumann M, Seibel P, Walter U, Klopstock T. Progression of myopathology in Kearns-Sayre syndrome: a morphological follow-up study. Acta Neuropathol (Berl) 1993;85:679-81. 587. Reichmann H, Naumann M, Hauck S, Janetzky B. Respiratory chain and mitochondrial deoxyribonucleic acid in blood cells from patients with focal and generalized dystonia. Mov Disord 1994;9:597-600. 588. Reichmann H, Janetzky B, Naumann M, Seibel P. Mitochondriale Myopathien. Psycho 1994;20:162-167. 589. Reichmann H, Goebel HH, Schneider C, Toyka KV. Familial mixed congenital myopathy with rigid spine phenotype. Muscle Nerve 1997;20:411-7. 590. Reimers CD, Rieckmann P. Neurologie und Sport (Editorial). Akt Neurol 2000;27:193-196. 591. * Reiners K, Hennerici M, Toyka KV. Zentrales und peripheres Nervensystem. In: Gerok W, Hartmann F, Schuster HP (Hrsg). Innere Medizin der Gegenwart. Zeidler H (Hrsg). Rheumatologie, Band I, München: Urban & Schwarzenberg 1990;118–122. 592. * Reiners K, Hennerici M, Toyka KV. Beziehungen zwischen Erkrankungen anderer Organsysteme und Bewegungsapparat: Nerven. In: Gerok W, Hartmann F, Schuster HP (Hrsg). Innere Medizin der Gegenwart. Zeidler H (Hrsg). Rheumatologie, Band I, München: Urban & Schwarzenberg 1990;717–726. 593. * Reiners K. Neuropathie und Motorik – Bedeutung der motoneuronalen Axon- und Myelinschädigung für die Nervenregeneration und funktionelle Kompensation bei Neuropathien, Stuttgart: Georg Thieme Verlag 1990. 594. * Reiners K. Therapeutische Alternativen bei Neuropathien. In: Rietbrock N (Hrsg). Pharmakologie und klinische Anwendung hochdosierter B-Vitamine. Darmstadt: Steinkopff Verlag 1991;77–85. 595. Reiners K. Diabetische Neuropathie. In: Bünte H, Domschke W, Meinertz T, Tölle R, Wilmanns W (Hrsg). Therapie-Handbuch, 4. Auflage. München - Wien - Baltimore: Urban & Schwarzenberg 1992;M31–32; Neufassung 1996;M29–30. 596. Reiners K. Therapie der Polyneuropathien bei Dysproteinämien und Neoplasien. (Editorial) Münch Med Wochenschr 1994;136:331–332. 597. Reiners K. Neuropathie und "neurotrope" Vitamine. VitaMinSpur 1995;10:146–149. 598. Reiners K, Haupt S. Die Wirkung der Vitamine B1, B6 und B12 auf den Einbau von Cholin in den Ischiasnerv des Kaninchens - Eine vergleichende Studie an gesunden Tieren und Tieren mit experimentell-allergischer Neuritis. VitaMinSpur 1996;11:74–84. 599. Reiners K, Hartung HP. Paraproteinämische Polyneuropathien. Nervenheilkunde 1996;15: 1– 600. Reiners K, Toyka KV. Management of cervical radiculopathy. Eur Neurology 1996;35:313–316. 601. Reiners K. Neurophysiologische und morphologische Aspekte der Nervenleitung. Grundlagen und Problematik des Leitungsblocks. Z. EEG-EMG 1997;28:96-102. 602. Reiners K. Neurophysiologische und morophologische Aspekte der Nervenleitung: II Befunde bei wichtigen neuropathischen Krankheitsbildern. Z. EEG - EMG 1997;28:121-129. 603. Reiners K. Vitamin B12-Mangelerkrankung. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg). Neurologie in Praxis und Klinik, 3. Aufl., Bd. II, Stuttgart: Thieme-Verlag 1999;798–802. 604. Reiners K. Vitamin E-Mangelerkrankung. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg). Neurologie in Praxis und Klinik, 3. Aufl., Bd. II, Stuttgart: Thieme-Verlag 1999;803–805. 605. Reiners K. Diabetische Neuropathien. Grundlagen, klinische Manifestationsformen und medikamentöse Therapie. Zentralbl Chir 1999;124:25-32. 606. Reiners K, Meinhold J. Diabetische Neuropathien. In Berger M (Hrsg): Diabetes mellitus. 2. Aufl. Urban & Fischer, München, 2000;593-614. 607. Reiners K, Meinhold J. Spraul M. Die neurologische Untersuchung. In: Berger M (Hrsg). Diabetes mellitus. 2. Aufl., Urban & Fischer Verlag, München - Jena, 2000;66-88. 608. Reiners K, Meinhold J. Diabetische Neuropathien. In: Berger M (Hrsg). Diabetes mellitus. 2. Auflage, Urban & Fischer Verlag, München - Jena 2000;593-614. 609. * Ricker K, Camacho LM, Grafe P, Lehmann-Horn F, Rudel R. Adynamia episodica hereditaria: what causes the weakness? Muscle Nerve 1989;12(11):883-91. 610. * Ricker K, Lehmann-Horn F, Moxley RT, 3rd. Myotonia fluctuans. Arch Neurol 1990;47(3):268- 611. * Ricker K, Moxley RT, 3rd. Autosomal dominant cramping disease. Arch Neurol 1990;47(7):810-2. 612. * Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, Heine R, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994;44(8):1448-52. 613. * Ricker K, Moxley RT, 3rd, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 1994;51(11):1095-102. 614. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Speich N, Reiners K, Schneider C, Moxley RT. 3rd. Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995;52:25-31. 615. Ricker K. Myotonic dystrophy and proximal myotonic myophathy. J Neurol 1999;246(5):334-8. 616. Ricker K, Grimm T, Koch MC, Schneider C, Kress W, Reimers CD, Schulte-Mattler W, Mueller- Myhsok B, Toyka KV, Mueller CR. Linkage of proximal myotonic myopathy to chromosome 3q. Neurology 1999;52:170-1. 617. Ricker K. The expanding clinical and genetic spectrum of the myotonic dystrophies. Acta Neurol Belg 2000;100(3):151-5. 618. Rieckmann P, Hartung H-P, Toyka K. Rekombinante Beta-Interferone: Immunmodulatorische Therapie der schubförmigen Multiplen Sklerose. Deutsches Ärzteblatt 1996;46:2362-2367. 619. * Rieckmann P, Tuscano JM, Kehrl JH. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B- lymphocyte function. Methods 1997;11:128-32. 620. Rieckmann P, Hartung HP. Neuroimmunologie. In: Herdegen T (Hrsg). Klinische Neurobiologie: molekularbiologische Grundlagen von Erkrankungen des Nervensystems. Spektrum Akademischer Verlag 1997. 621. * Rieckmann P, Altenhofen B, Riegel A, Kallmann B, Felgenhauer K. Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Mult Scler 1998;4:178-82. 622. * Rieckmann P, Turner T, Kilgannon P, Steinhoff B. The neuronal cell adhesion molecule, telencephalin is an indicator for temporal lobe dysfunction. The Lancet 1998;352:370-71. 623. Rieckmann P, Gold R, Toyka K. Erfolgreiche Therapie der multiplen Sklerose mit Beta- Interferonen. Der Internist 1999;40:119-125. 624. Rieckmann P, Smith K. Multiple Sclerosis: More than inflammation and demyelination. Trends Neurosci 2001;24:435-437. 625. Rieckmann P, Mäurer M. Anti-inflammatory strategies to prevent axonal damage in multiple sclerosis. Curr Opin Neurol 2002;15:361-370. 626. Rieckmann P, Mäurer M. Axonprotektion durch anti-inflammatorische Therapie. Akt Neurol 627. Rieckmann P, Toyka KV. Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002. Nervenarzt 2002;73(6):556-63. 628. Rosener M, Schwulera U, Menke G, Thrun A, Lissner R, Krauseneck P, Bogdahn U, Martin R. Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur Cytokine Netw 1993;4:189-95. 629. Rudel R, Ricker K, Lehmann-Horn F. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol 1993;50(11):1241-8. 630. Ruprecht K, Brück W, Hummel V, Kruse N, Seif F, Rieckmann P. Oncostatin M has immunoregulatory functions on human cerebral endothelial cells and is expressed in multiple sclerosis lesions. J Neuropathol Exp Neurol 2001;60:1087-1098. 631. Ruprecht K, Rieckmann P, Giess R. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. DMW 2001;126:812-814. 632. Ruprecht K, Stadelmann C, Hummel V, Klein O, Brück W, Rieckmann P. Brain dervied neurotrophic factor does not act on adult human cerebral endothelial cells. Neurosci Lett 330 2002;175-178. 633. Ruprecht K, Warmuth-Metz M, Waespe W, Gold R. Symptomatic hyperekplexia in a patient with multiple sclerosis. Neurology 2002;58:503-504. 634. * Salvetti M, Jung S, Chang SF, Will H, Schalke BC, Wekerle H. Acetylcholine receptor-specific T-lymphocyte clones in the normal human immune repertoire: target epitopes, HLA restriction, and membrane phenotypes. Ann Neurol 1991;29:508-16. 635. Samsam M, Frei R, Marziniak M, Martini R, Sommer C. Impaired sensory function in heterozygous P0 knockout mice is associated with nodal changes in sensory nerves. J Neurosci Res 2002;67:167-173. Mi W, Wessig C, Zielasek J, Toyka KV, Coleman MP, Martini R. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 2003; im Druck. 637. * Sawaki L, Cohen LG, Classen J, Bütefisch C. Enhancement of use-dependent plasticity by d- amphetamine. Neurology 2002;59:1262-4. 638. Schäfers M, Brinkhoff J, Neukirchen S, Marziniak M, Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310:113-116. 639. Schäfers M, Sommer C. Diseases of the peripheral nervous system causing pain: Polyneuropathies, in Pain in Peripheral Nerve Disease. Edited by Sommer C. Basel, Karger 2001. 640. Schäfers M, Geis C, Brors D, Yaksh T, Sommer C. Anterograde transport of tumor necrosis factor-alpha in experimental mononeuropathy. J Neurosci 2002;22:236-245. 641. Schäfers M, Schmidt C, Vogel C, Toyka KV, Sommer C. Tumor necrosis factor-alpha (TNF) regulates the expression of ICAM-1 predominantly through TNF receptor 1 after chronic constriction injury of mouse sciatic nerve. Acta Neuropathol (Berl) 2002;104(2):197-205. 642. Schäfers M, Geis C, Svensson CI, Luo ZD, Sommer C. Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 2003;17:791-804. 643. * Schäfers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci 2003;23:3028-3038. 644. Schäfers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve injury and TNF-induced hyperalgesia in the rat. Exp Neurol 2003; im Druck. 645. Schäfers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induced muscle hyperalgesia in rats. PAIN 2003;104:579-588. 646. Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-2521. 647. Schalke B, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;327:649-50. 648. Schalke B, Hofmann E, Reiners K, Kaiser W. Neuropathies and motor neuron diseases. Fleckenstein JL., Crues JV III, Reimers CD (Hrsg). Muscle imaging. New York - Heidelberg: Springer-Verlag 1996;203-214. 649. Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, Gold R, Toyka KV, Schachner M, Martini R. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J Neurosci 2000;20:729-735. 650. * Schmidt B, Stoll G, Hartung HP, Heininger K, Schäfer B, Toyka KV. Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. Ann Neurol 1990;28:70-7. 651. * Schmidt B, Stoll G, Toyka KV, Hartung HP. Rat astrocytes express interferon-gamma immunoreactivity in normal optic nerve and after nerve transection. Brain Res 1990;515:347-50. 652. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-87. 653. Schmidt J, Stürzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001;65(1):59-67. 654. Schmidt M, Kunkel M, Schuff-Werner P, Naumann M, Reichmann H, Reimers CD. Standardisierte aerobe Gehbelastung auf dem Laufband bei Gesunden sowie Patienten mit mitochondrialen und nicht-mitochondrialen Myopathien. Nervenarzt 1997;68:831-835. 655. Schmidt S, Stürzebecher S, Toyka KV, Gold R. Interferon- treatment of experimental autoimmune encephalomyelitis leads to rapid non-apoptotic termination of T cell infiltration. J Neurosci Res 2001;65:59-67. 656. Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung HP. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996;55:1205-9. 657. Schneider C, Dalakas MC, Toyka KV, Said G, Hartung HP, Gold R. T-cell apoptosis in inflammatory neuromuscular disorders associated with human immunodeficiency virus infection. Arch Neurol 1999;56:79-83. 658. Schneider C, Grimm T, Kress W, Sommer C, Müller CR. Hyperparathyroidism in a patient with proximal myotonic myopathy (PROMM). Neuromusc Disord 2000;10:481-483. 659. Schneider C, Matsumoto Y, Koyama K, Toyka KV, Hartung HP, Gold R. Experimental autoimmune myositis in the Lewis rat: lack of spontaneous Tcell apoptosis and therapeutic response to glucocorticosteroid application. J Immunol 2000;107:83-87. 660. Schneider C, Reiners K. Elektrophysiologische Diagnostik von Erkrankungen der neuromuskulären Übertragung. Klin Neurophysiol 2000;31:122-135. 661. Schneider C, Reiners K, Friedl W, Ebner R, Toyka KV. Involvement of the visual pathway in hereditary neuropathy with liability to pressure palsies. J Neurol 2000;247: 222-223. 662. Schneider C, Ziegler A, Ricker K, Grimm T, Kress W, Reimers CD, Meinck HM, Reiners K, Toyka KV. Proximal myotonic myopathy: Evidence for anticipation in families with linkage to chromosome 3q. Neurology 2000;55:383-388. 663. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46(2):79-82. 664. Schneider C, Reiners K, Toyka KV. Myotone Dystrophie (DM/Curschmann-Steinert-Erkrankung) und proximale myotone Myopathie (PROMM/Ricker-Syndrom) – Myotone Muskelerkrankungen mit multisystemischen Manifestationen. Nervenarzt 2001;72(8):618-624. 665. Schneider C, Wessig C, Müller CR, Brechtelsbauer D, Grimm T. Proximal myotonic myopathy and proximal myotonic dystrophy: Two different entities? Phenotypic variability in proximal myotonic syndromes. Neuromuscul Disord 2001;11:485-488. 666. Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25(2):286-288. 667. Schneider C, Müllges W. Entzündliche und degenerative Myopathien, Rhabdomyolyse und maligne Hyperthermie. J Anästh Intensivbehandl 2002;9:54-55. 668. Schneider-Gold C, Beck M, Wessig C, George A, Kele H, Reiners K, Toyka KV. Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy. Neurology 2003;60(3):500-2. 669. Schrank B, Götz R, Gunnersen JM, Ure JM, Toyka KV, Smith AG, Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 1997;94:9920-5. 670. Schröder JM, Toyka KV, Hartung HP. Peripheral Nerve Study Group, in Boppard, Germany, July 29th to August 1, 1993. Brain Pathol 1994;4:107-8. 671. Schröder JM, Toyka KV, Hartung HP. 11th meeting of the Peripheral Nerve Study Group (PNSG). "Klostergut Jakobsberg", Boppard, Germany 29 July-1 August 1993. Neuromuscul Disord 1995;5:75-7. 672. * Schroeter M, Franke C, Stoll G, Hoehn M. Dynamic changes of MRI abnormalities in relation to inflammation and glial responses after photothrombotic cerebral infarction in the rat brain. Acta Neuropathol 2001;101:114-122. 673. * Schroeter M, Jander S, Stoll G. CD8+ phagocytes in focal ischemia of the rat brain: Predominant origin from hematogenous macrophages and targeting to areas of pannecrosis. Acta Neuropathol 2001;101:440-448. 674. * Schroeter M, Jander S, Stoll G. Noninvasive induction of focal cerebral ischemia in mice by photothrombosis of cortical microvessels: Characterization of inflammatory responses. J Neurosci Meth 2002;117:43-49. 675. * Schwartzkopff B, Zierz S, Frenzel H, Block M, Neuen-Jacob E, Reiners K, Strauer BE. Ultrastructural abnormalities of mitochondria and deficiency of myocardial cytochrome c oxidase in a patient with ventricular tachycardia. Virchows Arch A Pathol Anat Histopathol 1991;419:63-8. 676. Sendtner M. Molecular biology of neurotrophic factors. Baillieres Clin Neurol 1995;4:575-91. 677. Sendtner M, Holtmann B, Hughes RA. The response of motoneurons to neurotrophins. Neurochem Res 1996;21:831-41. 678. Sendtner M, Götz R, Holtmann B, Escary JL, Masu Y, Carroll P, Wolf E, Brem G, Brulet P, Thoenen H. Cryptic physiological trophic support of motoneurons by LIF revealed by double gene targeting of CNTF and LIF. Curr Biol 1996;6:686-94. 679. Sendtner M. Neurotrophic factors for experimental treatment of motoneuron disease. Prog Brain Res 1996;109:365-71. 680. Sendtner M, Götz R, Holtmann B, Thoenen H. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motoneurons in adult mice. J Neurosci 1997;17:6999-7006. 681. Sendtner M. Neurotrophic factors: effects in modulating properties of the neuromuscular endplate. Cytokine Growth Factor Rev 1998;9:1-7. 682. * Shapira L, Stabholz A, Rieckmann P, Kruse N. Genetic polymorphism in the TNF-promotor region in families with localized early-onset periodontitis. J Periodontal Res 2001; 36:183-186. 683. * Sommer C, Lalonde A, Heckman HM, Rodriguez M, Myers RR. Quantitative neuropathology of a focal nerve injury causing hyperalgesia. J Neuropathol Exp Neurol 1995;54:635-43. 684. * Sommer C, Myers RR. Neurotransmitters in the spinal cord dorsal horn in a model of painful neuropathy and in nerve crush. Acta Neuropathol (Berl) 1995;90:478-85. 685. * Sommer C, Schröder JM. HLA-DR expression in peripheral neuropathies: the role of Schwann cells, resident and hematogenous macrophages, and endoneurial fibroblasts. Acta Neuropathol (Berl) 1995;89:63-71. 686. Sommer C, Myers RR. Vascular pathology in CCI neuropathy: a quantitative temporal study. Exp Neurol 1996;141:113-9. 687. Sommer C, Schmidt C, George A, Toyka KV. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci Lett 1997;237:45-8. 688. Sommer C, Myers RR. Pain in AIDS. In: Biebuyck J, Lynch C, Maze M, Saidman LJ, Yaksh TL, Zapol W (Hrsg). Anesthesia: Biologic Foundations. Section III: Peripheral Sensory Transduction and Transmission. Raven Press 1997;829-839. 689. Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 1998;151:138-42. 690. Sommer C, Schäfers M. Painful mononeuropathy in C57BL/Wld mice with delayed wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivity. Brain Res 1998;784:154-62. 691. Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 1998;74:83-91. 692. Sommer C. Zukünftige Strategien der medikamentösen Schmerztherapie. Nervenheilkunde 1998;17:176-181. Amyloid-Neuropathien. Med Welt 1998;49:548-554. 694. Sommer C. Thalidomide as a blocker of TNF production. Drugs of the Future 1999;24:67-75. 695. Sommer C, Petrausch S, Lindenlaub T, Toyka KV. Neutralizing antibodies to IL-1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett 1999; 270:25-28. 696. Sommer C: Cytokines and neuropathic pain, in Neuropathic pain: pathophysiology and treatment, vol 21. Edited by Hansson P, Fields H, Hill R, Marchettini P. Seattle, IASP press, 2001, pp 37-62. 697. Sommer C (ed): Pain in peripheral nerve disease. Basel, Karger, 2001. 698. Sommer C. Symptomatic treatment of painful neuropathies, in Pain in Peripheral Nerve Disease, vol 13. Edited by Sommer C. Basel, Karger, 2001, pp 171-195. 699. Sommer C. Zytokine bei neuropathischen Schmerzen. Anaesthesist 2001;50:416-426. 700. Sommer C, Lindenlaub T, Teuteberg P, Schäfers M, Hartung T, Toyka KV. Anti-TNF- neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res 2001;913(1):86-89. 701. Sommer C, Schäfers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 2001;6(2):67-72. 702. Sommer C. Pharmakologische Behandlung orofazialer Schmerzen. Schmerz 2002;16:381-388. 703. Sommer C, Lindenlaub T, Zillikens D, Toyka KV, Naumann M. Selective loss of cholinergic sudomotor fibers causes anhidrosis in Ross syndrome. Ann Neurol 2002;52(2):247-250. 704. Sommer C. Differenzialdiagnose der Gesichtsschmerzen. MMW 2003;145:30-33. 705. Stangel M, Toyka KV, Hartung HP, Giegerich G. Bacterial expression of a soluble T-cell receptor alpha chain. Biochem Biophys Res Commun 1994;202:1280-4. 706. Stangel M, Giegerich G, Torres-Nagel NE, H¸nig T, Hartung HP. Structural analysis of the rat T- cell receptor Tcra V4 gene family. Immunogenetics 1995;41:125-30. 707. Stangel M, Zettl UK, Mix E, Zielasek J, Toyka KV, Hartung HP, Gold R. H2O2 and nitric oxide- mediated oxidative stress induce apoptosis in rat skeletal muscle myoblasts. J Neuropathol Exp Neurol 1996;55:36-43. 708. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high dose intravenous immunoglobulins. Clin Neuropharmacol 1997;20:385-393. 709. Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological
autoimmune disorders. J Neurol Sci 1998;153(2):203-214. 710. Stanton-Hicks M, Baron R, Boas R, Gordh T, Harden N, Hendler N, Koltzenburg M, Raj P, Wilder R. Complex regional pain syndromes: Guidelines for therapy. Clin J Pain 1998;14:155-166. 711. * Stefan K, Kunesch E, Cohen LG, Benecke R, Classen J. Mechanisms of enhancement of motor cortical excitability induced by paired associative stimulation. J Physiol 2002;543:699–708. 712. * Stephan DA, Buist NR, Chittenden AB, Ricker K, Zhou J, Hoffman EP. A rippling muscle disease gene is localized to 1q41: evidence for multiple genes. Neurology 1994;44(10):1915-20. 713. Stienekemeier M, Herrmann T, Kruse N, Weishaupt A, Weilbach FX, Theofilopoulos AN, Giegerich G, Jung S, Gold R. Heterogeneity of TCR usage in experimental autoimmune neuritis
(EAN) of the Lewis rat. Brain 1999;122:523-53.
714. Stienekemeier M, Falk K, Rotzschke O, Weishaupt A, Schneider C, Toyka KV, Gold R, Strominger JL. Vaccination, prevention, and treatment of experimental autoimmune neuritis (EAN) by an oligomerized T cell epitope. Proc Natl Acad Sci U S A 2001;98(24):13872-7. 715. Stoll G, Schmidt B, Jander S, Toyka KV, Hartung HP. Presence of the terminal complement complex (C5b-9) precedes myelin degradation in immune-mediated demyelination of the rat peripheral nervous system. Ann Neurol 1991;30:147-55. 716. * Stoll G, Thomas C, Reiners K, Schober R, Hartung HP. Encephalo-myelo-radiculo-ganglionitis presenting as pandysautonomia. Neurology 1991;41:723-6. 717. * Stoll G, Reiners K, Schwartz A, Kaup FG, Althaus C, Freund HJ. Acute posterior multifocal placoid pigment epitheliopathy with cerebral involvement. J Neurol Neurosurg Psychiatry 1991;54:77-9. 718. Stoll G, Jander S, Jung S, Archelos J, Tamatani T, Miyasaka M, Toyka KV, Hartung HP. Macrophages and endothelial cells express intercellular adhesion molecule-1 in immune-mediated demyelination but not in Wallerian degeneration of the rat peripheral nervous system. Lab Invest 1993;68:637-44. 719. Stoll G, Müller S, Schmidt B, van der Meide P, Jung S, Toyka KV, Hartung HP. Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune encephalomyelitis. Am J Pathol 1993;142:1866-75. G. Regeneration im Nervensystem: Neue Strategien. Nervenheilkunde 2002;21:166-220. G, Jander S, Myers RR. Degeneration and regeneration of the peripheral nervous system:
from Augustus Waller´s observations to neuroinflammation. J Periph Nerv Syst 2002;7:13-27. G, Jander S, Schroeter M. Microglia and macrophage responses in cerebral ischemia. In: Microglia in the Regenerating and Degenerating CNS, Streit WJ (Hrsg). Springer, New York 2002; 125-151. G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation
and cytokine expression in the nervous system. In: Alzheimer C (Hrsg). Molecular and Cellular Biology of Neuroprotection in the CNS. Advances in Experimental Medicine and Biology, Landis Pub, New York 2002;Vol 513:87-113. 724. Stoll G, Jander S, Schroeter M. Microglia. In: Encyclopedia of the Human Brain, Elsevier Science (USA) 2002;Vol 3:29-41. 725. Stucky CL, Koltzenburg M. The low-affinity neurotrophin receptor p75 regulates the function but not the selective survival of specific subpopulations of sensory neurons. J Neurosci 1997;17:4398-405. 726. Stucky CL, DeChiara T, Lindsay RM, Yancopoulos GD, Koltzenburg M. Neurotrophin 4 is required for the survival of a subclass of hair follicle receptors. J Neurosci 1998;18:7040-6. 727. Stucky CL, Koltzenburg M, Schneider M, Engel MG, Albers KM, Davis BM. Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. J Neurosci 1999;19:8509-16. 728. Thies FL, Hartung HP, Giegerich G. Cloning and expression of the Campylobacter jejuni lon gene detected by RNA arbitrarily primed PCR. FEMS Microbiol Lett 1998;165:329-34. 729. Thies FL, Karch H, Hartung HP, Giegerich G. Cloning and expression of the dnaK gene of Campylobacter jejuni and antigenicity of heat shock protein 70. Infect Immun 1999;67:1194-200. 730. * Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Müller CR, Treves S. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1. Association with central core disease and alteration of calcium homeostasis. Hum Mol Gen 2001;10:2879-2887. 731. * Torebjörk E, Wahren LK, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoked pain in neuralgia. Pain 1995;63:11-20. 732. Toyka KV, Hartung HP, Steck A. Plasmapheresis in chronic demyelinating polyneuropathy. N Engl J Med 1992;326:1090-1. 733. Toyka KV. The immune system in neurologic disease: selected recent developments. Acta Neurol Belg 1996;96:185-8. 734. Toyka KV, Hartung HP. Chronic inflammatory polyneuritis and neuropathies. Curr Opin Neurol 735. Toyka KV, Hennerici M, Reiners K. Neurologische Untersuchung. In: Gerok W, Hartmann F, Schuster HP (Hrsg). Innere Medizin der Gegenwart. Zeidler H (Hrsg). Rheumatologie, Band I, München: Urban & Schwarzenberg 1990;196–202. 736. Toyka KV, Zielasek J, Ricker K, Adlkofer K, Suter U. Hereditary neuromyotonia: a mouse model associated with deficiency or increased gene dosage of the PMP22 gene. J Neurol Neurosurg Psychiatry 1997;63:812-3. 737. Toyka KV. Postlumbar puncture headache. J Neurol Neurosurg Psychiatry 1997;62:429. 738. Toyka KV. Neurology's witness to history: Leo Alexander. Neurology 1998;51:1772. 739. Toyka KV, Müller B, Reichmann H. "Atraumatic" Sprotte needle reduces the incidence of post- lumbar puncture headaches. Neurology 2002;59(7):1120; author reply 1120-1. 740. Toyka KV, Zielasek J, Stoll G. Myelin-derived glycolipids and animal models of Guillain-Barre syndrome. Ann Neurol 2002;51(4):532; author reply 532-3. 741. * Tucha O, Naumann M, Berg D, Alders G, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand 2001;103:49-52. 742. * Türp JC, John M, Nilges P, Jürgens J et al. Schmerzen im Bereich der Kaumuskultur und Kiefergelenke. Empfehlungen zur standardisierten Daignostik und Klassifikation von Patienten. Schmerz 2000;14:416-428. 743. Van der Knaap MS, van der Voorn P, Barkhof F, van Coster R, Krägeloh-Mann I, Feigenbaum A, Blaser S, Vies JSH, Rieckmann P, Pouwels PJW. A novel leukoencephalopathy with characteristic brain stem and spinal cord tract involvement and elevated white matter lactacte. Ann Neurol 2003;53:252-258. 744. van Gijn J, Reiners K, Toyka KV, Braakman R. Management of cervical radiculopathy. Eur Neurol 1995;35:309-20. 745. * Venken K, Meuleman J, Irobi J, Ceuterick C, Martini R, De Jonghe P, Timmerman V. Caspr1/Paranodin/Neurexin IV is most likely not a common disease causing gene for inherited peripheral neuropathies. Neuroreport 2001;12:2609-2614. 746. Vogel C, Lindenlaub T, Tiegs G, Toyka KV, Sommer C. Pain related behavior in TNF-receptor deficient mice, in Proceedings of the 9th World Congress on Pain, Progress in Pain Research and Management, vol 16. Edited by Devor M, Rowbotham MC, Wiesenfeld-Hallin Z. Seattle, IASP press 2000, pp 249-257. 747. Vogel C, Mössner R, Heinemann T, Riederer P, Gerlach M, Murphy DL, Lesch, K-P, Sommer, C. Absence of thermal hyperalgesia in serotonin transporter-deficient mice. J Neurosci 2003;23:708-715. 748. * Vordermark D, Becker G, Flenttje M, Richter S, Goerttler-Krauspe I, Koelbl O. Transcranial sonography: Transcranial sonography: integration into target volume definition for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2000 ;47:565-71. 749. Wagner S, Vince GH, Greif M, Rieckmann P, Roosen K, Tonn JC. IL-10 mediated enhancement of glioma cell migration/invasion is not related to MMP-expression. Anticancer Res 1997;17:4061-63. 750. * Wagner S, Füller T, Hummel V, Goldbrunner RH, Winkler A, Rieckmann P, Roosen K, Tonn JC. Primary cerebral endothelial cells in glioma neovascularization in vitro: role of MMPs and TIMPs. Proc AACR 2000;41:793-795. 751. Wagner S, Fueller T, Hummel V, Rieckmann P, Tonn JC. Influence of VEGF-R2 inhibition on MMP secretion and motility of human microvascular cerebral endothelial cells (HCEC). J Neurooncol 2003;62:221-231. 752. Warmuth-Metz M, Hofmann E, Naumann M, Becker T, Muller J. Beidseitige Chondrosarkome im Kleinhirnbrückenwinkel beim Maffucci-Syndrom. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992;156:500-2. 753. * Warmuth-Metz M, Becker G, Bendszus M, Solymosi S. Spinal canal stenosis in L-2- hydroxyglutaric aciduria. Arch Neurol 2000;57:1635-7. 754. * Warmuth-Metz M, Naumann M, Csoti I, Solymoshi L. Measurement of the midbrain diameter on routine magnetic resonance imaging. A simple and accurate method of differentiating between Parkinson´s disease and supranuclear palsy. Arch Neurol 2001;58:1076-1079. 755. Weilbach FX, Bogdahn U, Poot M, Apfel R, Behl C, Drenkard D, Martin R, Hoehn H. Melanoma- inhibiting activity inhibits cell proliferation by prolongation of the S-phase and arrest of cells in the G2 compartment. Cancer Res 1990;50:6981-6. 756. Weilbach FX, Toyka KV, Hartung HP. Orales, niedrig dosiertes Methotrexat bei chronisch- progredienter multipler Sklerose. Eine vorläufige kritische Analyse. Nervenarzt 1995;66:643-7. 757. Weilbach FX, Voltz R, Hohlfeld R, Hartung HP. Copolymer-1 in der Therapie der multiplen Sklerose. Nervenarzt 1995;66:473-7. 758. Weilbach FX, Hartung HP. Cladribin bei chronisch progredienter multipler Sklerose. Nervenarzt 1995;66:299-303. 759. Weilbach EX, Hartung HP. Immunmodulation bei multipler Sklerose: Linomide. Nervenarzt 760. Weilbach FX, Jung S, Hartung HP, Toyka KV, Giegerich G. T-cell receptor V beta-element expression in peripheral nerves of Lewis rats suffering from experimental autoimmune neuritis. J Neuroimmunol 1997;79:69-75. 761. Weilbach FX, Hartung HP. Physikalisches Trauma und multiple Sklerose. Nervenarzt 762. Weilbach FX, Kreß W, Straßburg HM, Müller CR, Gold R. Aktuelle Diagnostik bei Muskeldystrophien. Neue Entwicklungen, Untersuchungsmethoden und Fallbeispiele. Nervenarzt 1999;70:89-10. 763. Weilbach FX, Rieckmann P, Gold R, Toyka KV. Multiple Sklerose: kritische Betrachtung umstrittener und komplementärmedizinischer Therapien auf der Grundlage aktueller Hypothesen zur Pathogenese. Akt Neurol 2001;28:31-38. 764. Weilbach FX, Rieckmann P, Gold R, Toyka KV. Multiple Sklerose: Kritische Betrachtung umstrittener und komplementär-medizinischer Therapien auf der Grundlage aktueller Hypothesen zur Pathogenese. Akt Neurol 2001;28:31-38. 765. Weilbach FX, Toyka KV. Does Down's syndrome protect against multiple sclerosis? Eur Neurol 2002;47(1):52-5. 766. Weishaupt A, Giegerich G, Jung S, Gold R, Enders U, Pette M, Hayasaka K, Hartung HP, Toyka KV. T cell antigenic and neuritogenic activity of recombinant human peripheral myelin P2 protein. J Neuroimmunol 1995;63:149-56. 767. Weishaupt A, Gold R, Gaupp S, Giegerich G, Hartung HP, Toyka KV. Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. Proc Natl Acad Sci U S A 1997;94:1338-43. A, Jander S, Brück W, Stienekemeier M, Hartung T, Toyka KV, Stoll G, Gold R. Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1 type cytokines and inducible nitric oxide snthase. J Immunol 2000;165:7157-7163. 769. Weishaupt A, Brück W, Hartung T, Toyka KV, Gold R. Schwann cell apoptosis in experimental autoimmune neuritis and the functional role of TNF-α. Neurosci Lett 2001;306(1-2):77-80. 770. Weishaupt A, Schönrock LM, Stienekemeier M, Toyka KV, Gold R. Glucocorticosteroids modulate antigen-induced T cell apoptosis in experimental autoimmune neuritis and cause T cell proliferation in situ. Acta Neuropathol (Berl) 2001;102(1):75-82. 771. Weishaupt A, Kuhlmann T, Schönrock LM, Toyka KV, Brück W, Gold R. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol (Berl) 2002;104(4):385-90. 772. Weiß H, Rastan V, Müllges W, Wagner RF, Toyka KV. Psychotic symptoms and emotional distress in patients with Guillain-Barre syndrome. Eur Neurol 2002;47(2):74-8. 773. Wessig C, Buchwald B, Toyka KV, Martini R. Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction. Acta Neuropath 2001;101:239-244. 774. Wessig C, Buchwald B, Toyka KV, Martini R. Miller Fisher syndrome: immunofluorescence and immunoelectron microscopic localization of IgG at the mouse neuromuscular junction. Acta Neuropathol (Berl) 2001;101(3):239-44. 775. Wessig C, Klein R, Schneider M, Toyka KV, Naumann M, Sommer C. Neuropathology and antibody-binding studies in anti-amphiphysin-associated stiff person syndrome with encephalopathy. Neurology 2003;61:195-198. 776. Will M, Häußler M, Straßburg HM, Naumann M. Einfache videogestützte Ganganalyse beim spastischen Spitzfuß. Z Kinderheilkunde 2002;150:316-323. 777. * Willison H, Stoll G, Toyka KV, Berger T, Hartung HP. Autoimmunity and inflammation in the peripheral nervous system (Meeting Report). Trends Neurosci 2002;25(3):127-129. 778. Winkler J, Bogdahn U, Becker G, Durant W, Brunner FX, Eckstein M, Brawanski A, Warmuth M, Mertens HG. Surgical intervention and heparin-anticoagulation improve prognosis of rhinogenic/otogenic and posttraumatic meningitis. Acta Neurol Scand 1994;89:293-8. 779. * Winterholler M, Claus D, Bockelbrink A, Borasio GD, Pongratz D, Schrank B, Toyka KV, Neundörfer B. Empfehlungen der bayerischen Muskelzentren in der DGM zur Heimbeatmung bei neuromuskularen Erkrankungen Erwachsener. Nervenarzt 1997;68:351-7. 780. * Wintermeyer P, Krüger R, Kuhn W, Müller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schöls L, Epplen JT, Riess O. Mutation analysis and association studies of the UCHL1 gene in German sporadic and familial Parkinson's disease patients. Neuroreport 2000;14:2079-82. 781. * Wolters A, Sandbrink F, Schlottmann A, Kunesch E, Stefan K, Cohen LG, Benecke R, Classen J. A temporally asymmetric Hebbian rule governing plasticity in the human motor cortex. J Neurophysiol 2003; 89:2339-4235. 782. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, Lipton R, Loeser JD, Payne R, Torebjörk E et al. Towards a mechansim-based classification of pain? Pain 1998;77:227-229. 783. * Woolf CJ, Koltzenburg M. Mechanism-based classifications of pain and analgesic drug discovery. In: Bountra C, Munglani R, Schmidt WK (Hrsg). Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. New York: Marcel Dekker 1999. 784. Woydt M, Krone A, Becker G, Schmidt K, Roggendorf W, Roosen K. Correlation of intra- operative ultrasound with histopathologic findings after tumour resection in supratentorial gliomas. A method to improve gross total tumour resection. Acta Neurochir (Wien) 1996;138:1391-8. 785. * Woydt M, Greiner K, Perez J, Becker G, Krone A, Roosen K. Transcranial duplex-sonography in intracranial hemorrhage. Evaluation of transcranial duplex-sonography in the diagnosis of spontaneous and traumatic intracranial hemorrhage. Zentralbl Neurochir 1996;57:129-35. 786. * Woydt M, Becker G, Krone A. Diagnostik des Schädel-Hirn-Trauma. Bogdahn U, Becker G, Schlachetzki F (Hrsg). Echosignalverstärker und transkranielle Farbduplex-Sonographie. Blackwell, Berlin, Wien u.a. 1998;317-322. 787. * Wrabetz L, Feltri ML, Quattrini A, Imperiale D, Previtali S, D'Antonio M, Martini R, Yin X, Trapp BD, Xhou L, Chiu SY, Messing A. P0 overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000;148:1021-1033. 788. Wunderlich S, Reiners K, Gasser T, Naumann M. Cervical dystonia in monozygotic twins: case report and review of the literature. Mov Disord 2001;16(4):714-8. 789. Wunderlich S, Csoti I, Reiners K, Günthner-Lengsfeld T, Schneider C, Becker G, Naumann M. Camptocormia in Parkinson's disease mimicked by focal myositis of the paraspinal muscles. Mov Disord 2002;17(3):598-600. 790. Wunderlich S, Güntner-Lengsfeld T, Schneider C, Becker G, Naumann M. Focal myositis of paraspinal muscles mimicking camptocormia in Parkinson´s disease. Mov Disord 2002;17(3):598-600. 791. * Yaksh TL, Horais KA, Tozier N, Allen JE, Rathbun M, Rossi SS, Sommer C, Meschter C, Richter P, Page L, Hildebrand K. Chronically infused intrathecal morphine in dogs. Anesthesiology 2003;99:174-187. 792. Zenner K, Gold R, Meurers B, Reichmann H. Die mitochondrialen Enzephalomyopathien. Kearns-Sayre-Syndrom, MELAS und MERRF im Vergleich. Nervenarzt 1990;61:597-603. 793. Zettl UK, Gold R, Toyka KV, Hartung HP. In situ demonstration of T cell activation and elimination in the peripheral nervous system during experimental autoimmune neuritis in the Lewis rat. Acta Neuropathol (Berl) 1996;91:360-7. 794. Zettl UK, Gold R, Hartung HP, Toyka KV. Apoptotic cell death of T-lymphocytes in experimental autoimmune neuritis of the Lewis rat. Neurosci Lett 1994;176:75-9. 795. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the Lewis rat. J Neuropathol Exp Neurol 1995;54:540-7. 796. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell Immunol 1997;178:1-8. 797. Zielasek J, Tausch M, Toyka KV, Hartung HP. Production of nitrite by neonatal rat microglial cells/brain macrophages. Cell Immunol 1992;141:111-20. 798. Zielasek J, Archelos JJ, Toyka KV, Hartung HP. Expression of intercellular adhesion molecule-1 on rat microglial cells. Neurosci Lett 1993;153:136-9. 799. Zielasek J, Jung S, Schmidt B, Ritter G, Hartung HP, Toyka K. Effects of ganglioside administration on experimental autoimmune neuritis induced by peripheral nerve myelin or P2-specific T cell lines. J Neuroimmunol 1993;43:103-11. 800. Zielasek J, Ritter G, Magi S, Hartung HP, Toyka KV. A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994;241:475-80. 801. Zielasek J, Jung S, Gold R, Liew FY, Toyka KV, Hartung HP. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;58:81-8. 802. Zielasek J, Reichmann H, Kunzig H, Jung S, Hartung HP, Toyka KV. Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat. Neurosci Lett 1995;184:129-32. 803. Zielasek J, Martini R, Toyka KV. Functional abnormalities in P0-deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 1996;19:946-52. 804. Zielasek J, Müller B, Hartung HP. Inhibition of cytokine-inducible nitric oxide synthase in rat microglia and murine macrophages by methyl-2,5-dihydroxycinnamate. Neurochem Int 1996;29:83-7. 805. Zielasek J, Hartung HP. Molecular mechanisms of microglial activation. Adv Neuroimmunol 806. Zielasek J, Martini R, Suter U, Toyka KV. Neuromyotonia in mice with hereditary myelinopathies. Muscle Nerve 2000;23:696-701. 807. * Zimprich A, Grahowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidmann K, Kern P, Müller-Mysak B, Riedel L, Bader M, Müller T, Castro M, Meisinger T, Strom TM, Gasser T. Mutations in the gene encoding varepsilon-sacroglycan cause myoclonus syndrome. Nature Genetics 2001;29:66-69.

Source: http://neurologie.uk-wuerzburg.de/fileadmin/uk/neurologie/dokumente/publikationen1990-2000.pdf

semenza.es

Endoscopic Carpal Tunnel Release Surgical Technique Table of Contents Indications and Contraindications• Indications: The MicroAire Carpal Tunnel Release System is for Indications / Contraindications . i use in patients diagnosed with carpal tunnel syndrome that is not associated with, or secondary to, any other known pathology

academic.evergreen.edu

and pains would be overdiagnosed.Ó to 2.3 percent above the 1990 level, to Some preexisting categories were re- 1,369 million metric tons. tested but none removed. In the past, The governmentÕs own carbon emis- 2 emissions may put gay activists lobbied to have homosex- reduction goal beyond reach sion numbers will be published later uality erased from the DSM register;